<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id>
    <journal-id journal-id-type="publisher-id">narcancer</journal-id>
    <journal-title-group>
      <journal-title>NAR Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2632-8674</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10782923</article-id>
    <article-id pub-id-type="doi">10.1093/narcan/zcad063</article-id>
    <article-id pub-id-type="publisher-id">zcad063</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00030</subject>
        <subject>AcademicSubjects/SCI00980</subject>
        <subject>AcademicSubjects/SCI01060</subject>
        <subject>AcademicSubjects/SCI01140</subject>
        <subject>AcademicSubjects/SCI01180</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Cancer Data Resource</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>TSCRE: a comprehensive database for tumor-specific <italic toggle="yes">cis</italic>-regulatory elements</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Peng</surname>
          <given-names>Guanjie</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Bingyuan</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zheng</surname>
          <given-names>Mohan</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Luowanyue</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Huiqin</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Mengni</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liang</surname>
          <given-names>Yuan</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Tianjian</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Luo</surname>
          <given-names>Xiaotong</given-names>
        </name>
        <aff><institution>Guangdong Institute of Gastroenterology, Department of General Surgery</institution>, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5774-8568</contrib-id>
        <name>
          <surname>Shi</surname>
          <given-names>Xianping</given-names>
        </name>
        <!--xianping.shi@gzhmu.edu.cn-->
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4161-1292</contrib-id>
        <name>
          <surname>Ren</surname>
          <given-names>Jian</given-names>
        </name>
        <!--renjian@sysucc.org.cn-->
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5692-8903</contrib-id>
        <name>
          <surname>Zheng</surname>
          <given-names>Yueyuan</given-names>
        </name>
        <!--zhengyy86@mail.sysu.edu.cn-->
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 13509645425; Email: <email>zhengyy86@mail.sysu.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Jian Ren. Tel: +86 13751761881; Email: <email>renjian@sysucc.org.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Xianping Shi. Tel: +86 13570066303; Email: <email>xianping.shi@gzhmu.edu.cn</email></corresp>
      <fn id="FN1">
        <p>The first four authors should be regarded as joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-01-11">
      <day>11</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>11</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <volume>6</volume>
    <issue>1</issue>
    <elocation-id>zcad063</elocation-id>
    <history>
      <date date-type="accepted">
        <day>31</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>18</day>
        <month>11</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>28</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of NAR Cancer.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="zcad063.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p><italic toggle="yes">Cis</italic>-regulatory elements (CREs) and super <italic toggle="yes">cis-</italic>regulatory elements (SCREs) are non-coding DNA regions which influence the transcription of nearby genes and play critical roles in development. Dysregulated CRE and SCRE activities have been reported to alter the expression of oncogenes and tumor suppressors, thereby regulating cancer hallmarks. To address the strong need for a comprehensive catalogue of dysregulated CREs and SCREs in human cancers, we present TSCRE (<ext-link xlink:href="http://tscre.zsqylab.com/" ext-link-type="uri">http://tscre.zsqylab.com/</ext-link>), an open resource providing tumor-specific and cell type-specific CREs and SCREs derived from the re-analysis of publicly available histone modification profiles. Currently, TSCRE contains 1 864 941 dysregulated CREs and 68 253 dysregulated SCREs identified from 1366 human patient samples spanning 17 different cancer types and 9 histone marks. Over 95% of these elements have been validated in public resources. TSCRE offers comprehensive annotations for each element, including associated genes, expression patterns, clinical prognosis, somatic mutations, transcript factor binding sites, cancer-type specificity, and drug response. Additionally, TSCRE integrates pathway and transcript factor enrichment analyses for each study, enabling in-depth functional and mechanistic investigations. Furthermore, TSCRE provides an interactive interface for users to explore any CRE and SCRE of interest. We believe TSCRE will be a highly valuable platform for the community to discover candidate cancer biomarkers.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="zcad063figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32200538</award-id>
        <award-id>32200542</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Shenzhen Science and Technology Innovation Commission</institution>
            <institution-id institution-id-type="DOI">10.13039/501100010877</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>JCYJ20220530144815036</award-id>
        <award-id>JCYJ20230807110309019</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Guangdong Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003453</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2021A1515011334</award-id>
        <award-id>2023A1515011976</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>82170177/H0809</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Sun Yat-sen University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100002402</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>ZSQYBRJH0025</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p><italic toggle="yes">Cis</italic>-regulatory elements (CREs), including enhancers, promoters, and silencers, are crucial for controlling gene expression during development (<xref rid="B1" ref-type="bibr">1–3</xref>). Super <italic toggle="yes">cis-</italic>regulatory elements (SCREs), characterized by large clusters of regulatory regions, are essential in determining cell differentiation and identity (<xref rid="B4" ref-type="bibr">4–6</xref>). Numerous CREs and SCREs have been identified across human tissues and diseases. In the context of human cancers, the aberrant activity of CREs and SCREs can lead to the dysregulation of oncogenes and tumor suppressors, disrupting normal cellular processes and promoting cancer hallmarks such as proliferation, invasion and metastasis (<xref rid="B7" ref-type="bibr">7–9</xref>). Dysregulations in enhancers, super-enhancers, silencers, and promoters are common epigenetic alterations. For example, aberrant regulation of enhancers and super-enhancers have been frequently observed in various cancers, resulting in the upregulation of key oncogenes, such as <italic toggle="yes">MYC</italic> and <italic toggle="yes">FOXQ1</italic> in colorectal cancer (<xref rid="B10" ref-type="bibr">10</xref>), as well as <italic toggle="yes">FOXC1</italic> and <italic toggle="yes">MET</italic> in triple-negative breast cancer (<xref rid="B11" ref-type="bibr">11</xref>). Additionally, many silencers, characterized by extensive broad H3K27me3 modification, exhibit a significant reduction in H3K27me3 modification size in human tumors, thereby promoting the activation of oncogenes such as <italic toggle="yes">MYH11</italic> and <italic toggle="yes">EGFR</italic> (<xref rid="B12" ref-type="bibr">12</xref>). Moreover, dysregulation of promoters, including promoter hypermethylation and alterations in H3K4me3 along with H3K27ac, is frequently observed in cancer (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>). These dysregulations of CREs and SCREs exhibit specificity towards particular cancer types or subtypes, reflecting the unique epigenomic landscapes of different cells and tumors (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>). Recent studies have highlighted the potential of dysregulated CREs and SCREs as promising targets for cancer diagnosis and treatment (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). For instance, the exclusive activity of the <italic toggle="yes">INSM1</italic> promoter in insulinoma tumors has been leveraged for adenoviral therapy in insulinoma treatment (<xref rid="B19" ref-type="bibr">19</xref>). Therefore, the accumulating evidence for the essential roles of dysregulated CREs and SCREs in cancer biology, emphasizes the urgent need to comprehensively catalog dysregulated CREs and SCREs across various human cancer types.</p>
    <p>Previous studies have demonstrated the efficiency and robustness of histone modification profiling in identifying distinct classes of regulatory elements (<xref rid="B20" ref-type="bibr">20–22</xref>). For example, promoters can be identified by the histone mark H3K4me3, enhancers by H3K4me1, active regulatory elements by H3K27ac, and repressive elements by either H3K27me3 or H3K9me3 (<xref rid="B18" ref-type="bibr">18</xref>). With the rapid accumulation of chromatin immunoprecipitation sequencing (ChIP-seq) data on histone marks, several CRE and SCRE databases have been developed, such as ENCODE (<xref rid="B23" ref-type="bibr">23</xref>), CistromeDB (<xref rid="B24" ref-type="bibr">24</xref>), ChIP-Atlas (<xref rid="B25" ref-type="bibr">25</xref>), SEdb v2.0 (<xref rid="B26" ref-type="bibr">26</xref>), SEA v3.0 (<xref rid="B27" ref-type="bibr">27</xref>) and dbSUPER (<xref rid="B28" ref-type="bibr">28</xref>). These databases serve as valuable resources for investigating <italic toggle="yes">cis-</italic>regulatory elements, but they primarily focus on profiling of CREs or SCREs within individual tissues and cells. There is an urgent need for the collection of feature-specific dysregulated elements in human cancers (e.g. tumor-specific, metastasis-specific, and subtype-specific elements). Additionally, besides super-enhancers, other broad regulatory elements, such as super repressive elements and broad H3K4me3 regions, have also been implicated in cancer (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>), emphasizing the importance of their efficient identification and characterization. Moreover, further research on dysregulated CREs and SCREs heavily relies on reliable regulatory annotation, including genetic and epigenetic annotation, as well as association analyses involving transcription factors, cancer pathways, clinical prognosis, and response to anticancer drugs. Therefore, it is necessary to develop a comprehensive database dedicated to cancer-associated CREs and SCREs, elucidating their regulatory mechanisms in a highly cancer-specific context.</p>
    <p>Here, we present TSCRE (<ext-link xlink:href="http://tscre.zsqylab.com/" ext-link-type="uri">http://tscre.zsqylab.com/</ext-link>), a comprehensive open resource of tumor-specific and cell type-specific CREs and SCREs derived through extensive re-analyses of public histone modification profiling data in human cancers (Figure <xref rid="F1" ref-type="fig">1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). Using TSCRE, users are able to efficiently and intuitively explore dysregulated CREs or SCREs of interest in various cancer types of contrast experiments, such as ‘tumor vs. nonmalignant’, ‘metastasis vs. primary’, "mutant vs. wildtype’. We believe this platform will greatly benefit the research community by aiding in the screening of candidate CREs and SCREs, as well as facilitating the identification of relevant transcriptional regulators in human cancers.</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Overall design and construction of TSCRE.</p>
      </caption>
      <graphic xlink:href="zcad063fig1" position="float"/>
    </fig>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection</title>
      <p>A systematic search was conducted to find out cancer-associated histone modification profiles. Firstly, the GEO and SRA database were searched using keywords relating to nine of better-known histone markers (including H3K27ac, H3K4me3, H3K4me2, H3K4me1, H3K36me3, H3K9ac, H3K79me2, H3K9me3 and H3K27me3), along with the term ‘Genome binding/occupancy profiling by high throughput sequencing’. Datasets were restricted to human studies published before February 2023. Then we performed a manual screening and reserved studies that met the following criteria: 1) inclusion of tumor tissue or cancer cell lines, 2) samples in each study that could be compared based on a specific biological condition, including ‘tumor vs. non-malignant,’ ‘metastasis vs. primary,’ ‘mutant vs. wild-type’ or ‘subtype1 vs. subtype2’ and 3) presence of at least two biological replicates for each condition. In addition, matched RNA-seq data from the corresponding studies were downloaded when available.</p>
      <p>The following additional datasets were collected: long-range interactions between genes and distal regulatory regions, including pan-cancer ‘enhancer-to-gene’ links from TCGA ATAC-seq projects (<xref rid="B29" ref-type="bibr">29</xref>), Hi-C loops from 3D Genome Browser (<xref rid="B30" ref-type="bibr">30</xref>), and HiChIP loops from matched studies. Other <italic toggle="yes">cis-</italic>regulatory elements were obtained from public resources, containing DNase I-hypersensitive sites (DHSs) from the ENCODE project (<xref rid="B23" ref-type="bibr">23</xref>), CREs from the FANTOM5 project (<xref rid="B31" ref-type="bibr">31</xref>), enhancers from GeneHancer (<xref rid="B32" ref-type="bibr">32</xref>), silencers from SilencerDB (<xref rid="B33" ref-type="bibr">33</xref>) and super-enhancers from a recent publication (<xref rid="B34" ref-type="bibr">34</xref>). Multi-omics data of pan-cancer tissues and cell lines were extracted from TCGA and DepMap projects, containing mRNA expression, somatic mutations, chromatin accessibility, clinical data and CRISPR scores (<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>). In addition, we also obtained enhancer RNA (eRNA) expression from the TCeA Portal and mutations from COSMIC (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>). TFBSs from the ENCODE project and TF target genes from KnockTF were also included in our database (<xref rid="B39" ref-type="bibr">39</xref>). Lastly, we acquired pharmacogenomic data from GDSC2 and CTRP2, which involved drug response data from 198 and 545 compounds in various cancer lineages (<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Data preprocessing</title>
      <p>Raw ChIP-seq reads were trimmed using Trim-galore (version 0.6.6) and then aligned to the GRCh38 genome (ENSEMBL release 84) using BWA (version 0.7.17) with default parameters (<xref rid="B42" ref-type="bibr">42</xref>). Then uniquely mapped reads were extracted and sorted using SAMtools (version 1.7) program with the ‘-q 1’ option (<xref rid="B43" ref-type="bibr">43</xref>). PCR duplicates were removed using the Picard MarkDuplicates tool (version 2.26.2), and ENCODE blacklist regions were excluded using BEDtools (version v2.26.0) (<xref rid="B44" ref-type="bibr">44</xref>). MACS2 (Model-Based Analysis of ChIP-Seq, version 2.2.6) was applied to call peaks (refer to CREs) with the options ‘-q 0.01 –extsize = 146 –nomodel’ (<xref rid="B45" ref-type="bibr">45</xref>). Samples meeting all the following criteria are retained for further analysis: (i) duplication rates &lt;0.5; (ii) mapping rates &gt;0.6; (iii) at least 5 million usable fragments for narrow marks and 15 million for broad marks; (iv) peaks &gt;500 and fraction of reads in peaks (FRiP) ≥1%.</p>
      <p>Similarly, raw RNA-seq reads were processed to remove low-quality reads using Trim-galore (version 0.6.6) with default parameters. High-quality reads were then aligned to the GRCh38 genome using HISAT2 (version 7.2.0) and gene quantification was performed using the htseq-count program (version 0.11.3) with default settings (<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). Samples with a mapping rate &gt;0.6 and at least 10 million usable fragments were selected for differential gene expression analysis. The DESeq2 package or Wilcoxon test (≥8 samples in each given condition) were applied to identify differentially expressed genes, employing the criteria of ‘adjusted <italic toggle="yes">P</italic>-value &lt;0.05 and absolute fold-change &gt;1.5’ (<xref rid="B48" ref-type="bibr">48</xref>).</p>
    </sec>
    <sec id="SEC2-3">
      <title>Dysregulated CRE/SCRE identification</title>
      <p>Peaks modified by different histone markers, as identified in the previous section, were considered as CREs. DiffBind (version 3.6.5) was then used to compare CREs between two conditions and those with a fold change ≥1.5 and FDR &lt;0.05 were selected as dysregulated CREs (<xref rid="B49" ref-type="bibr">49</xref>).</p>
      <p>Among SCREs, the most extensively studied subset are super-enhancers, usually marked by H3K27ac modification. Rank Order of Super Enhancers (ROSE) is a commonly used method for identifying super-enhancers (<xref rid="B5" ref-type="bibr">5</xref>). Briefly, ROSE merged enhancer elements within a 12.5-kb distance and arranges them in decreasing order of intensities. Super-enhancers are then defined as stitching elements exhibiting a tangent slope with an inflection point value ≥1. ROSE (version 1.0) was also applied to identify super repressive elements enriched with H3K27me3 modification (<xref rid="B6" ref-type="bibr">6</xref>). Considering the potential variations in the stitching distance for different histone marks, we initially determined the most suitable distance for each histone mark by analyzing the histone modification peaks across various cell types from the ENCODE project. We merged peaks within different stitching distances for each dataset, ranging from 0.5 to 24 kb with 0.5 kb increments, and identified SCREs at each distance. We then counted the total number of peaks contained in SCREs and selected the optimal distance when the increasing number at that distance stabilized compared to the previous distance. As shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>, H3K27ac and H3K27me3 peaks within SCREs reached stability at 12 and 5 kb, respectively, which were close to the reported values of 12.5 and 4 kb. After obtaining the optimal distance for each histone marker (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>), we used ROSE to identify SCREs for each sample. Next, we employed the BEDtools multiinter function to find a consensus SCRE set of unique genomic intervals presenting in at least two samples for each study. Finally, DiffBind program was applied to identify the dysregulated SCREs and those with a fold change ≥1.5 and <italic toggle="yes">P</italic> value &lt;0.05 were selected.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Annotations of dysregulated CRE/SCREs</title>
      <p>We validated the accuracy of CREs and SCREs by checking whether they overlapped with regulatory regions obtained from ENCODE, FANTOM5, GeneHancer, SilencerDB and other existing literature (<xref rid="B34" ref-type="bibr">34</xref>). We then applied three gene annotation strategies to find the associated genes for each element. First, we mapped CREs to the nearest genes using the Homer annotatePeaks.pl function (<xref rid="B50" ref-type="bibr">50</xref>), while mapping SCREs to the nearest or overlapping genes with the help of ROSE_geneMapper.py function. Second, we associated distal CREs and SCREs with ATAC-seq-linked genes, which were established by the TCGA consortium based on the correlation between ATAC-Seq peaks and the expression levels of neighboring genes. Lastly, we assigned distal CREs and SCREs to their respective genes using Hi-C and HiChIP loops. To assist researchers in identifying the most relevant regulatory genes, we calculated mRNA expression level for each associated gene from available matched samples, pan-cancer tissues as well as cancer cell lines, and examine the survival outcome in cancer samples. Furthermore, associated TFBSs and somatic mutations were assigned to each CRE and SCRE using the BEDTools intersect program.</p>
    </sec>
    <sec id="SEC2-5">
      <title>Assessing cancer-type specificity and examining associations with drug response</title>
      <p>The cancer-type specificity of each regulatory element was determined by calculating its overlap with other elements in TSCRE, as well as by assessing the chromatin accessibility and enhancer RNA activity in the TCGA pan-cancer landscape. Additionally, we employed calcPhenotype function from the oncoPredict package to impute the drug response from GDSC and CTRP cancer cell lines to TCGA patient samples, after which we calculated the associations of each regulatory element with the imputed drug response (<xref rid="B51" ref-type="bibr">51</xref>). To achieve this, we trained linear ridge regression models using the expression levels and drug sensitivity scores of the cancer cell lines from GDSC and CTRP. These models were then applied to the expression levels of TCGA samples, generating predicted scores for drug sensitivity for each TCGA patient. Next, we evaluated the accessibility of each regulatory element in the corresponding TCGA patients using TCGA ATAC-seq signals, and further determined the associations between regulatory element accessibility and imputed drug response using Spearman correlation. Associations with |<italic toggle="yes">R</italic>| &gt;0.3 and FDR &lt;0.05 were considered as significant associations in each cancer type.</p>
    </sec>
    <sec id="SEC2-6">
      <title>Identification of enriched TFs and biological functions</title>
      <p>Enrichment analysis of TF binding sites was conducted for dysregulated elements using the Homer findMotifs.pl function and LOLA program, setting one condition's dysregulated CRE/SCREs as the foreground and the other's as the background (<xref rid="B52" ref-type="bibr">52</xref>). To gain a deeper understanding of the context specificity and essentiality of each significant TF (FDR &lt; 0.01), we analyzed their corresponding expression levels in TCGA pan-cancer samples, gene dependency scores in cancer cell lines, and clinical prognosis. Furthermore, we introduced the KnockTF datasets and presented the potential downstream targets.</p>
      <p>For biological functions, we employed the solo mode of Cistrome-GO program to perform pathway enrichment analysis by using the collections of gene sets from KEGG and GO-BP (<xref rid="B53" ref-type="bibr">53</xref>). A minimum-hypergeometric test was conducted to identify the enriched pathways with an FDR &lt; 0.2. The detailed information about association analyses were listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>.</p>
    </sec>
    <sec id="SEC2-7">
      <title>Identification of tumor-specific and cell type-specific CREs and SCREs</title>
      <p>To identify more CREs and SCREs that regulate oncogenes in tumor-specific and cell type-specific manners, we first selected the CREs and SCREs that demonstrated gained active modification or lost repressive modification in tumor samples compared with nonmalignant samples. We then employed a prioritization approach to select the most promising candidates from all association analyses based on the specific criteria. These criteria included: (i) enhanced expression of the associated gene, (ii) ranking within the top 5 for chromatin accessibility, (iii) ranking within the top 5 for eRNA activity and (iv) exhibiting an overlap of at least 50% in length with fewer than two <italic toggle="yes">cis-</italic>regulatory elements found in other cancer types. CREs and SCREs that met all these criteria were considered to have a high confidence level of tumor specificity and cancer-type specificity. Additionally, CREs and SCREs that satisfied three criteria achieved a median confidence level. Furthermore, CREs and SCREs that met two criteria were regarded as having a low confidence level.</p>
    </sec>
    <sec id="SEC2-8">
      <title>Web interface implementation</title>
      <p>All the metadata and analysis results were stored and managed using MySQL tables. The web interfaces were implemented using Hyper Text Markup Language (HTML), Cascading Style Sheets (CSS), and JavaScript (JS). To visualize all the analysis results, various statistical diagrams were shown by EChars and UCSC Genome Browser were implemented.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Data summary</title>
      <p>In the current release, TSCRE contains 138 carefully curated histone ChIP-seq datasets covering 1366 patient samples across 9 different histone marks and 17 different cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). Of these, 1034 samples were collected from patient tissues, while 332 samples were derived from cancer cell lines (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1C</xref>). Across 17 cancer types, a total of 18 64 941 dysregulated CREs and 68 253 dysregulated SCREs were identified in one of the following conditions: ‘tumor versus nonmalignant’, ‘metastasis versus primary’, ‘mutant versus wildtype’ and ‘subtype1 versus subtype2’ (Table <xref rid="tbl1" ref-type="table">1</xref>). Notably, approximately 95% of CREs and 99% of SCREs have been validated in at least one public resource, demonstrating the reproducibility and robustness of our data analyses.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>Statistics of dysregulated CREs and SCREs in TSCRE</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th colspan="2" align="center" rowspan="1">Tumor versus nonmalignant</th>
              <th colspan="2" align="center" rowspan="1">Metastasis versus primary</th>
              <th colspan="2" align="center" rowspan="1">Mutant versus wildtype</th>
              <th colspan="2" align="center" rowspan="1">Subtype1 versus Subtype2</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1">
                <inline-graphic xlink:href="zcad063figu1.jpg"/>
              </th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Colorectal cancer</td>
              <td rowspan="1" colspan="1">143 662</td>
              <td rowspan="1" colspan="1">4878</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Uterine leiomyoma</td>
              <td rowspan="1" colspan="1">68 805</td>
              <td rowspan="1" colspan="1">2481</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Gastric cancer</td>
              <td rowspan="1" colspan="1">58 686</td>
              <td rowspan="1" colspan="1">2339</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Prostate cancer</td>
              <td rowspan="1" colspan="1">40 833</td>
              <td rowspan="1" colspan="1">2422</td>
              <td rowspan="1" colspan="1">68805</td>
              <td rowspan="1" colspan="1">2170</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Liver cancer</td>
              <td rowspan="1" colspan="1">32 847</td>
              <td rowspan="1" colspan="1">1187</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kidney cancer</td>
              <td rowspan="1" colspan="1">32 209</td>
              <td rowspan="1" colspan="1">3000</td>
              <td rowspan="1" colspan="1">8</td>
              <td rowspan="1" colspan="1">98</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">341 735</td>
              <td rowspan="1" colspan="1">8502</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Glioma</td>
              <td rowspan="1" colspan="1">18 657</td>
              <td rowspan="1" colspan="1">1481</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Esophageal cancer</td>
              <td rowspan="1" colspan="1">7841</td>
              <td rowspan="1" colspan="1">442</td>
              <td rowspan="1" colspan="1">2145</td>
              <td rowspan="1" colspan="1">172</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">20 562</td>
              <td rowspan="1" colspan="1">560</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Follicular lymphoma</td>
              <td rowspan="1" colspan="1">257</td>
              <td rowspan="1" colspan="1">170</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Diffuse large B cell lymphoma</td>
              <td rowspan="1" colspan="1">339</td>
              <td rowspan="1" colspan="1">82</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Natural killer T-cell lymphoma</td>
              <td rowspan="1" colspan="1">27 784</td>
              <td rowspan="1" colspan="1">713</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lung cancer</td>
              <td rowspan="1" colspan="1">25 066</td>
              <td rowspan="1" colspan="1">1584</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Breast cancer</td>
              <td rowspan="1" colspan="1">543 577</td>
              <td rowspan="1" colspan="1">17 615</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">296 088</td>
              <td rowspan="1" colspan="1">11 537</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Head and neck cancer</td>
              <td rowspan="1" colspan="1">51 649</td>
              <td rowspan="1" colspan="1">3276</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">9796</td>
              <td rowspan="1" colspan="1">1052</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pancreatic cancer</td>
              <td rowspan="1" colspan="1">7198</td>
              <td rowspan="1" colspan="1">81</td>
              <td rowspan="1" colspan="1">59 098</td>
              <td rowspan="1" colspan="1">1669</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Osteosarcoma</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">193</td>
              <td rowspan="1" colspan="1">207</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Chronic lymphocytic leukemia</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">7101</td>
              <td rowspan="1" colspan="1">535</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Total</td>
              <td rowspan="1" colspan="1">1 059 410</td>
              <td rowspan="1" colspan="1">41 751</td>
              <td rowspan="1" colspan="1">130 249</td>
              <td rowspan="1" colspan="1">4316</td>
              <td rowspan="1" colspan="1">7101</td>
              <td rowspan="1" colspan="1">535</td>
              <td rowspan="1" colspan="1">668 181</td>
              <td rowspan="1" colspan="1">21651</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To facilitate further functional and mechanistic studies, systematic association analyses are integrated into TSCRE. First, we provide detailed gene annotation, associated TFBSs and somatic mutations for each dysregulated element. In addition to the nearest or overlapping genes, a total of 220 681 distal CREs and 44 639 distal SCREs were associated with specific genes through distal element-to-promoter loops. Additionally, 80.09% (1 493 595/1 864 941) of CREs and 99.96% (68 224/68 253) of SCREs exhibited one or more TFBSs. Moreover, 31 705 dysregulated CREs and 27 029 dysregulated SCREs had associated somatic mutations in the corresponding cancer type. These findings highlight the importance of <italic toggle="yes">cis-</italic>regulatory elements in addressing key issues related to cancer biology. Second, we accessed the cancer-type specificity of each regulatory element. Notably, a large proportion of CREs (83.8%) and SCREs (59.58%) show overlap with other regulatory elements in three or fewer cancer types, indicating a high degree of cancer-type specificity (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>). Third, we assessed the association between regulatory elements and imputed drug response in patients across various cancer types, providing a more direct and powerful evaluation of the role of CREs and SCREs in targeted therapy compared to <italic toggle="yes">in vitro</italic> cell lines. We obtained 20 812 864 associations between CRE accessibility and the imputed drug response, consisting of 6 531 763 associations detected from CTRP and 14 281 101 associations from GDSC. Similarly, 672 248 associations were found in SCREs. These data provide valuable insights into the potential impact of regulatory elements on drug response in cancer patients. The dysregulation of CRE and SCREs can influence transcriptional programs by facilitating or restricting the accessibility of transcript factor binding sites in a tumor-specific and cell type-specific manner, thereby mediating the activation of cancer-associated pathways. We further identified all enriched TFs and pathways for each study to promote follow-up functional and mechanistic studies. Additionally, we collected a comprehensive dataset comprising 683 TF knockout microarrays and RNA-seq data from the KnockTF database, enabling the identification of potential downstream targets.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Data access</title>
      <p>TSCRE provides a user-friendly web interface, allowing users to intuitively explore and search any CRE or SCRE:</p>
      <p><bold>Explore</bold>. Users can select the cancer type(s), histone marker(s) and condition(s) of interest either through an interactive heatmap or a summary list. For example, if users are interested in studying tumor-specific regulatory elements in colorectal cancer, they can easily choose ‘colorectal cancer’ and ‘Tumor vs Nonmalignant’ from the metadata selection facet (Figure <xref rid="F2" ref-type="fig">2A</xref>). Subsequently, the relevant heatmap cells are retrieved (Figure <xref rid="F2" ref-type="fig">2A</xref>), and upon clicking on a specific cell, a dataset list is presented (Figure <xref rid="F2" ref-type="fig">2B</xref>). Data in TSCRE is organized into two layers: CRE and SCRE. By clicking on ‘CRE’ or ‘SCRE’ in a dataset of interest, users will be directed to a detailed page that provides study and sample details, CRE/SCRE information, as well as TF and pathway enrichment analysis. The CRE/SCRE information section shows all dysregulated elements and summarizes the number of association analyses conducted for each element (Figure <xref rid="F2" ref-type="fig">2C</xref>). Clicking on individual CRE ID shows the detailed information for each dysregulated element. The TF enrichment analysis section displays significantly enriched TFs identified in this study (Figure <xref rid="F2" ref-type="fig">2D</xref>). Some visualized figures are generated in real time to allow investigation of the cancer-type specificity and potential targets of enriched TFs (Figure <xref rid="F2" ref-type="fig">2E</xref>). For instance, HNF4A, a well-established gastrointestinal-specific transcription factor (<xref rid="B54" ref-type="bibr">54</xref>), ranked as the second most enriched TF in colorectal cancer-specific CREs (Figure <xref rid="F2" ref-type="fig">2D</xref>). HNF4A exhibited the highest expression levels in both colorectal cancer tissues and cell lines, regulated many target genes and was essential for the viability of the majority of colorectal cancer cells in the unbiased high-throughput CRISPR screening (Figure <xref rid="F2" ref-type="fig">2E</xref>). The pathway enrichment analysis section displays all enriched pathways associated with dysregulated elements and the top 10 pathways are shown in a bubble plot.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>A schematic workflow of the browse interface in TSCRE. <bold>(A)</bold> TSCRE provides an interactive heatmap and a summary list to browse and select studies of interest. Snapshot of results for colorectal cancer in ‘Tumor vs Nonmalignant’ condition. <bold>(B)</bold> A summary list is shown when clicking on a specific heatmap cell. Data in TSCRE is organized into two layers: CRE and SCRE. <bold>(C)</bold> The CRE information section shows all dysregulated elements and summarizes the number of association analyses conducted for each element. <bold>(D)</bold> Snapshot of HNF4A as the second most enriched TF. <bold>(E)</bold> Click the ‘eye’ button to get the expression levels of HNF4A in pan-cancer tissues and cell lines, the gene dependency scores, as well as potential target genes.</p>
        </caption>
        <graphic xlink:href="zcad063fig2" position="float"/>
      </fig>
      <p><bold>Search</bold>. TSCRE provides three modes to query the database, according to your interest in specific genes, transcription factors, and genomic regions. All the search results are summarized with real-time statistical diagrams and further filtered by check boxes.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Tumor-specific CREs and SCREs identified in TSCRE</title>
      <p>TSCRE is a valuable resource to explore and discover cancer biomarkers. Through the analysis of the ‘Tumor vs Nonmalignant’ comparison, we identified 918 CREs and 405 SCREs that exhibited a high confidence level of tumor specificity and cancer-type specificity (see Materials and methods). Additionally, 24 821 CREs and 1948 SCREs met the criteria for the median confidence level. Furthermore, we identified 151 273 CREs and 3880 SCREs with a low confidence level (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). These <italic toggle="yes">cis-</italic>regulatory elements may aid in the discovery of candidate cancer biomarkers and enhance our knowledge of regulatory mechanisms in cancer. For example, <italic toggle="yes">CD70</italic> is reported as a tumor-specific biomarker in kidney cancer, which promotes immune escape by inducing cytotoxic effects on B and T lymphocytes. Using TSCRE, we found <italic toggle="yes">CD70</italic> was regulated by a distal enhancer (‘Pair_41_CRE330’) in kidney cancer, which were further validated by FANTOME5 enhancers and pan-cancer ATAC-seq links (Figure <xref rid="F3" ref-type="fig">3A</xref>). Notably, this enhancer exhibits a significant increase in H3K27ac signal in kidney cancer compared to nonmalignant samples (Figure <xref rid="F3" ref-type="fig">3B</xref>), which coincides with the upregulation of <italic toggle="yes">CD70</italic> (Figure <xref rid="F3" ref-type="fig">3C</xref>). Moreover, this enhancer demonstrated a high degree of cell type specificity, as it ranked first in chromatin accessibility (Figure <xref rid="F3" ref-type="fig">3D</xref>) and second in eRNA activity (Figure <xref rid="F3" ref-type="fig">3E</xref>) within kidney cancer. Especially, only a single CRE in colon cancer exhibits partial overlap with this enhancer (Figure <xref rid="F3" ref-type="fig">3A</xref>). These findings indicate this enhancer associated with <italic toggle="yes">CD70</italic> regulation is highly specific to kidney cancer. Another notable case is <italic toggle="yes">MERTK</italic> gene, which is known as an oncogene that promotes breast cancer progression (<xref rid="B12" ref-type="bibr">12</xref>). Consistently, nonmalignant samples encompass repressive CREs (known as silencers in SilencerDB) associated with <italic toggle="yes">MERTK</italic>. However, across all subtypes of breast cancer, there is a significant loss of H3K27me3 modification, coinciding with the upregulation of MERTK in most subtypes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3</xref>). These results suggest that dysregulated CREs in TSCRE are highly specific to tumorigenesis and underscore their potential role in elucidating the molecular mechanisms underlying pathogenesis.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>The detailed information of a distal CRE for <italic toggle="yes">CD70</italic>. <bold>(A)</bold> Visualization of ‘Pair_41_CRE330’ using UCSC Genome Browser. (B, C) A significant increase in H3K27ac signal <bold>(B)</bold> and mRNA expression <bold>(C)</bold> was observed in kidney cancer. (D, E) Kidney cancer exhibits the highest chromatin accessibility <bold>(D)</bold> and the second-highest level of eRNA activity <bold>(E)</bold> within this CRE.</p>
        </caption>
        <graphic xlink:href="zcad063fig3" position="float"/>
      </fig>
      <p>Similarly, dysregulated SCREs are also highly specific to tumorigenesis (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3B</xref>). For example, <italic toggle="yes">PDX1</italic>, a potential tumor marker in colorectal cancer (<xref rid="B55" ref-type="bibr">55</xref>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S4A</xref>), contains both a lost repressive SCRE (‘Pair_18_SCRE66’) and a gained active SCRE (‘Pair_10_SCRE127’, a super-enhancer cataloged in Reference (<xref rid="B34" ref-type="bibr">34</xref>)) in colorectal cancer. In nonmalignant tissues, <italic toggle="yes">PDX1</italic> is characterized by the presence of H3K27me3 signal and the absence of H3K27ac. In contrast, it undergoes a reduction in H3K27me3 and an increase in H3K27ac during tumorigenesis, accompanied by elevated mRNA expression. Additionally, this SCRE shows high cell type specificity, ranking first in both accessibility and eRNA activity.</p>
      <p>In addition, TSCRE serves as a valuable platform for identifying potential therapeutic targets associated with dysregulated elements. An exemplary case is the EGFR gene, which exhibits frequent overexpression in basal breast cancer and contributes to the aggressive behavior of this subtype (<xref rid="B56" ref-type="bibr">56</xref>). Recent investigations have explored EGFR inhibitors, such as gefitinib and erlotinib, as potential treatment modalities for basal breast cancer (<xref rid="B56" ref-type="bibr">56</xref>). Encouragingly, our findings demonstrate a significant association between the drug response to gefitinib and erlotinib and a gained active SCRE ("Pair_92_SCRE61’, a super-enhancer cataloged in Reference (<xref rid="B34" ref-type="bibr">34</xref>)) in EGFR specific to basal breast cancer (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S5</xref>). Remarkably, within TSCRE, a substantial proportion of CREs (628 993 out of 1 864 941) and SCREs (25 964 out of 68 253) are linked to drugs, suggesting their potential involvement in drug response or as therapeutic targets.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>TSCRE is a comprehensive open resource for providing dysregulated CREs and SCREs through the re-analysis of publicly available ChIP-seq data. In comparison to other existing databases, TSCRE possesses the following advantages: (i) To the best of our knowledge, TSCRE is the first comprehensive database focusing specifically on <italic toggle="yes">cis-</italic>regulatory elements in a highly cancer-associated context; (ii) TSCRE is the only database emphasizing the roles of both CREs and SCREs. (iii) In addition to super-enhancers, TSCRE also provides super repressive elements and other broad regions, which were modified with repressive marks (e.g. H3K27m3, H3K9me3) or other active marks (e.g. H3K4me3, H3K36me3). (iv) TSCRE provides detailed annotations for each CRE and SCRE, including gene annotation, mRNA expression, clinical prognosis, associated TFBSs, associated mutations and cancer-type specificity. These annotations assist biologists in identifying relevant biological features and discover novel cancer biomarkers. (v) TSCRE assesses the associations between dysregulated elements and drug response in cancer patients, potentially enabling more direct and impactful target therapy. (vi) TSCRE integrates the results of pathway and TF enrichment analysis to facilitate follow-up functional and mechanistic studies.</p>
    <p>In the future, TSCRE will be continuously updated as new histone modification profiling data become available in public databases. We also plan to incorporate other epigenetic marks, such as DNA methylation, and more drug response dataset into TSCRE. Additionally, we strongly encourage users to contribute to TSCRE by uploading their own data.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>zcad063_Supplemental_Files</label>
      <media xlink:href="zcad063_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>YYZ was supported by the National Natural Science Foundation of China (32200538), Shenzhen Science and Technology Innovation Commission (JCYJ20220530144815036, JCYJ20230807110309019), the Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University (ZSQYBRJH0025). XPS was supported by the National Natural Science Foundation of China (82170177/H0809), the Natural Science Foundation of Guangdong Province (2021A1515011334 and 2023A1515011976). XTL was supported by the National Natural Science Foundation of China (32200542).</p>
    <p><italic toggle="yes">Author contributions</italic>: <bold>Y.Y. Zheng:</bold> conceptualization, resources, supervision, funding acquisition, methodology, writing–original draft, writing–review and editing. <bold>J. Ren:</bold> resources, supervision, methodology, writing–review and editing. <bold>X.P. Shi:</bold> resources, supervision, funding acquisition, methodology, writing–review and editing. <bold>G.J. Peng:</bold> data curation, data analysis, writing–original draft, writing–review and editing. <bold>B.Y. Liu:</bold> data curation, data analysis, writing–original draft, writing–review and editing. <bold>M.H. Zheng:</bold> website construction, visualization, methodology, writing–review and editing. <bold>L.W.Y. Zhang:</bold> website construction, visualization, methodology, writing–review and editing. <bold>H.Q. Li:</bold> website construction, methodology. <bold>MN. Liu:</bold> data curation, writing–review and editing. <bold>Y. Liang:</bold> data curation, writing–review and editing. <bold>T.J. Chen:</bold> website construction, methodology. <bold>X.T. Luo:</bold> resources, methodology and funding acquisition.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>No new data were generated or analysed in support of this research.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcad063#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Cancer Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>The Young Scientists Fund of the National Natural Science Foundation of China [32200538, 32200542]; Shenzhen Science and Technology Innovation Commission [JCYJ20220530144815036, JCYJ20230807110309019]; The Natural Science Foundation of Guangdong Province [2021A1515011334, 2023A1515011976]; The National Natural Science Foundation of China [82170177/H0809]; Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University [ZSQYBRJH0025].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ong</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Corces</surname><given-names>V.G.</given-names></string-name></person-group><article-title>Enhancer function: new insights into the regulation of tissue-specific gene expression</article-title>. <source>Nat. Rev. Genet.</source><year>2011</year>; <volume>12</volume>:<fpage>283</fpage>–<lpage>293</lpage>.<pub-id pub-id-type="pmid">21358745</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pang</surname><given-names>B.</given-names></string-name>, <string-name><surname>van Weerd</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Hamoen</surname><given-names>F.L.</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>M.P.</given-names></string-name></person-group><article-title>Identification of non-coding silencer elements and their regulation of gene expression</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><year>2023</year>; <volume>24</volume>:<fpage>383</fpage>–<lpage>395</lpage>.<pub-id pub-id-type="pmid">36344659</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andersson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Sandelin</surname><given-names>A.</given-names></string-name></person-group><article-title>Determinants of enhancer and promoter activities of regulatory elements</article-title>. <source>Nat. Rev. Genet.</source><year>2020</year>; <volume>21</volume>:<fpage>71</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">31605096</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Madani Tonekaboni</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Haibe-Kains</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lupien</surname><given-names>M.</given-names></string-name></person-group><article-title>Large organized chromatin lysine domains help distinguish primitive from differentiated cell populations</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>499</fpage>.<pub-id pub-id-type="pmid">33479238</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whyte</surname><given-names>W.A.</given-names></string-name>, <string-name><surname>Orlando</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Hnisz</surname><given-names>D.</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Kagey</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Rahl</surname><given-names>P.B.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Master transcription factors and mediator establish super-enhancers at key cell identity genes</article-title>. <source>Cell</source>. <year>2013</year>; <volume>153</volume>:<fpage>307</fpage>–<lpage>319</lpage>.<pub-id pub-id-type="pmid">23582322</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Loh</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Tng</surname><given-names>J.Q.</given-names></string-name>, <string-name><surname>Lim</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Raju</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lieberman Aiden</surname><given-names>E.</given-names></string-name>, <string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Manikandan</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>H3K27me3-rich genomic regions can function as silencers to repress gene expression via chromatin interactions</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>719</fpage>.<pub-id pub-id-type="pmid">33514712</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hsieh</surname><given-names>I.Y.</given-names></string-name>, <string-name><surname>He</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>B.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>B.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>G.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis</article-title>. <source>Biomed. Pharmacother.</source><year>2020</year>; <volume>123</volume>:<fpage>109728</fpage>.<pub-id pub-id-type="pmid">31846842</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Loven</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hoke</surname><given-names>H.A.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Lau</surname><given-names>A.</given-names></string-name>, <string-name><surname>Orlando</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Vakoc</surname><given-names>C.R.</given-names></string-name>, <string-name><surname>Bradner</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title>. <source>Cell</source>. <year>2013</year>; <volume>153</volume>:<fpage>320</fpage>–<lpage>334</lpage>.<pub-id pub-id-type="pmid">23582323</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>X.</given-names></string-name>, <string-name><surname>Su</surname><given-names>J.</given-names></string-name>, <string-name><surname>Rodriguez</surname><given-names>B.</given-names></string-name>, <string-name><surname>Xi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes</article-title>. <source>Nat. Genet.</source><year>2015</year>; <volume>47</volume>:<fpage>1149</fpage>–<lpage>1157</lpage>.<pub-id pub-id-type="pmid">26301496</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Saiakhova</surname><given-names>A.</given-names></string-name>, <string-name><surname>Corradin</surname><given-names>O.</given-names></string-name>, <string-name><surname>Luppino</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Lovrenert</surname><given-names>K.</given-names></string-name>, <string-name><surname>Bartels</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Morrow</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Mack</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Dhillon</surname><given-names>G.</given-names></string-name>, <string-name><surname>Beard</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome</article-title>. <source>Nat. Commun.</source><year>2017</year>; <volume>8</volume>:<fpage>14400</fpage>.<pub-id pub-id-type="pmid">28169291</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Maryam</surname><given-names>A.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ramakrishnan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>V.W.S.</given-names></string-name>, <string-name><surname>Cheuk</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>2242</fpage>.<pub-id pub-id-type="pmid">33854062</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Meng</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Yi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Broad genic repression domains signify enhanced silencing of oncogenes</article-title>. <source>Nat. Commun.</source><year>2020</year>; <volume>11</volume>:<fpage>5560</fpage>.<pub-id pub-id-type="pmid">33144558</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bouras</surname><given-names>E.</given-names></string-name>, <string-name><surname>Karakioulaki</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bougioukas</surname><given-names>K.I.</given-names></string-name>, <string-name><surname>Aivaliotis</surname><given-names>M.</given-names></string-name>, <string-name><surname>Tzimagiorgis</surname><given-names>G.</given-names></string-name>, <string-name><surname>Chourdakis</surname><given-names>M.</given-names></string-name></person-group><article-title>Gene promoter methylation and cancer: an umbrella review</article-title>. <source>Gene</source>. <year>2019</year>; <volume>710</volume>:<fpage>333</fpage>–<lpage>340</lpage>.<pub-id pub-id-type="pmid">31202904</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qamra</surname><given-names>A.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>M.</given-names></string-name>, <string-name><surname>Padmanabhan</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>J.J.T.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Leong</surname><given-names>Y.S.</given-names></string-name>, <string-name><surname>Lee Lim</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Ooi</surname><given-names>W.F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma</article-title>. <source>Cancer Discov.</source><year>2017</year>; <volume>7</volume>:<fpage>630</fpage>–<lpage>651</lpage>.<pub-id pub-id-type="pmid">28320776</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mack</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Pajtler</surname><given-names>K.W.</given-names></string-name>, <string-name><surname>Chavez</surname><given-names>L.</given-names></string-name>, <string-name><surname>Okonechnikov</surname><given-names>K.</given-names></string-name>, <string-name><surname>Bertrand</surname><given-names>K.C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Erkek</surname><given-names>S.</given-names></string-name>, <string-name><surname>Federation</surname><given-names>A.</given-names></string-name>, <string-name><surname>Song</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling</article-title>. <source>Nature</source>. <year>2018</year>; <volume>553</volume>:<fpage>101</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">29258295</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>G.H.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Qi</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Teng</surname><given-names>X.Q.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H.H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>J.</given-names></string-name></person-group><article-title>Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance</article-title>. <source>J. Exp. Clin. Cancer Res.</source><year>2021</year>; <volume>40</volume>:<fpage>174</fpage>.<pub-id pub-id-type="pmid">34011395</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name></person-group><article-title>Super-enhancer function and its application in cancer targeted therapy</article-title>. <source>NPJ Precis. Oncol.</source><year>2020</year>; <volume>4</volume>:<fpage>2</fpage>.<pub-id pub-id-type="pmid">32128448</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hou</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>W.</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>F.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name></person-group><article-title>Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma</article-title>. <source>J. Transl. Med.</source><year>2011</year>; <volume>9</volume>:<fpage>39</fpage>.<pub-id pub-id-type="pmid">21481255</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tseng</surname><given-names>A.W.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Breslin</surname><given-names>M.B.</given-names></string-name>, <string-name><surname>Lan</surname><given-names>M.S.</given-names></string-name></person-group><article-title>Tumor-specific promoter-driven adenoviral therapy for insulinoma</article-title>. <source>Cell Oncol (Dordr)</source>. <year>2016</year>; <volume>39</volume>:<fpage>279</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">26902080</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muratani</surname><given-names>M.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>N.</given-names></string-name>, <string-name><surname>Ooi</surname><given-names>W.F.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Qamra</surname><given-names>A.</given-names></string-name>, <string-name><surname>Tay</surname><given-names>S.T.</given-names></string-name>, <string-name><surname>Malik</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements</article-title>. <source>Nat. Commun.</source><year>2014</year>; <volume>5</volume>:<fpage>4361</fpage>.<pub-id pub-id-type="pmid">25008978</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heintzman</surname><given-names>N.D.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Hon</surname><given-names>G.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ching</surname><given-names>C.W.</given-names></string-name>, <string-name><surname>Hawkins</surname><given-names>R.D.</given-names></string-name>, <string-name><surname>Barrera</surname><given-names>L.O.</given-names></string-name>, <string-name><surname>Van Calcar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ching</surname><given-names>K.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome</article-title>. <source>Nat. Genet.</source><year>2007</year>; <volume>39</volume>:<fpage>311</fpage>–<lpage>318</lpage>.<pub-id pub-id-type="pmid">17277777</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akhtar-Zaidi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Cowper-Sal-lari</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corradin</surname><given-names>O.</given-names></string-name>, <string-name><surname>Saiakhova</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bartels</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Balasubramanian</surname><given-names>D.</given-names></string-name>, <string-name><surname>Myeroff</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lutterbaugh</surname><given-names>J.</given-names></string-name>, <string-name><surname>Jarrar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kalady</surname><given-names>M.F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Epigenomic enhancer profiling defines a signature of colon cancer</article-title>. <source>Science</source>. <year>2012</year>; <volume>336</volume>:<fpage>736</fpage>–<lpage>739</lpage>.<pub-id pub-id-type="pmid">22499810</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hitz</surname><given-names>B.C.</given-names></string-name>, <string-name><surname>Gabdank</surname><given-names>I.</given-names></string-name>, <string-name><surname>Hilton</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Kagda</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>B.</given-names></string-name>, <string-name><surname>Myers</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Sud</surname><given-names>P.</given-names></string-name>, <string-name><surname>Jou</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>New developments on the Encyclopedia of DNA Elements (ENCODE) data portal</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D882</fpage>–<lpage>D889</lpage>.<pub-id pub-id-type="pmid">31713622</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mei</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D729</fpage>–<lpage>D735</lpage>.<pub-id pub-id-type="pmid">30462313</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zou</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Ohta</surname><given-names>T.</given-names></string-name>, <string-name><surname>Miura</surname><given-names>F.</given-names></string-name>, <string-name><surname>Oki</surname><given-names>S.</given-names></string-name></person-group><article-title>ChIP-Atlas 2021 update: a data-mining suite for exploring epigenomic landscapes by fully integrating ChIP-seq, ATAC-seq and bisulfite-seq data</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>W175</fpage>–<lpage>W182</lpage>.<pub-id pub-id-type="pmid">35325188</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Song</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>SEdb 2.0: a comprehensive super-enhancer database of human and mouse</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D280</fpage>–<lpage>D290</lpage>.<pub-id pub-id-type="pmid">36318264</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name></person-group><article-title>SEA version 3.0: a comprehensive extension and update of the Super-Enhancer archive</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D198</fpage>–<lpage>D203</lpage>.<pub-id pub-id-type="pmid">31667506</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name></person-group><article-title>dbSUPER: a database of super-enhancers in mouse and human genome</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D164</fpage>–<lpage>D171</lpage>.<pub-id pub-id-type="pmid">26438538</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corces</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Granja</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Shams</surname><given-names>S.</given-names></string-name>, <string-name><surname>Louie</surname><given-names>B.H.</given-names></string-name>, <string-name><surname>Seoane</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>W.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Groeneveld</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>C.K.</given-names></string-name>, <string-name><surname>Cho</surname><given-names>S.W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The chromatin accessibility landscape of primary human cancers</article-title>. <source>Science</source>. <year>2018</year>; <volume>362</volume>:<fpage>eaav1898</fpage>.<pub-id pub-id-type="pmid">30361341</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Song</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kuang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>D.</given-names></string-name>, <string-name><surname>Choudhary</surname><given-names>M.N.K.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The 3D genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions</article-title>. <source>Genome Biol.</source><year>2018</year>; <volume>19</volume>:<fpage>151</fpage>.<pub-id pub-id-type="pmid">30286773</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noguchi</surname><given-names>S.</given-names></string-name>, <string-name><surname>Arakawa</surname><given-names>T.</given-names></string-name>, <string-name><surname>Fukuda</surname><given-names>S.</given-names></string-name>, <string-name><surname>Furuno</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hasegawa</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hori</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ishikawa-Kato</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kaida</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kaiho</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kanamori-Katayama</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>FANTOM5 CAGE profiles of human and mouse samples</article-title>. <source>Sci. Data</source>. <year>2017</year>; <volume>4</volume>:<fpage>170112</fpage>.<pub-id pub-id-type="pmid">28850106</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fishilevich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Nudel</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rappaport</surname><given-names>N.</given-names></string-name>, <string-name><surname>Hadar</surname><given-names>R.</given-names></string-name>, <string-name><surname>Plaschkes</surname><given-names>I.</given-names></string-name>, <string-name><surname>Iny Stein</surname><given-names>T.</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kohn</surname><given-names>A.</given-names></string-name>, <string-name><surname>Twik</surname><given-names>M.</given-names></string-name>, <string-name><surname>Safran</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>GeneHancer: genome-wide integration of enhancers and target genes in GeneCards</article-title>. <source>Database (Oxford)</source>. <year>2017</year>; <volume>2017</volume>:<fpage>bax028</fpage>.<pub-id pub-id-type="pmid">28605766</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeng</surname><given-names>W.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>X.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>R.</given-names></string-name></person-group><article-title>SilencerDB: a comprehensive database of silencers</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D221</fpage>–<lpage>D228</lpage>.<pub-id pub-id-type="pmid">33045745</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hnisz</surname><given-names>D.</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Lau</surname><given-names>A.</given-names></string-name>, <string-name><surname>Saint-Andre</surname><given-names>V.</given-names></string-name>, <string-name><surname>Sigova</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Hoke</surname><given-names>H.A.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Super-enhancers in the control of cell identity and disease</article-title>. <source>Cell</source>. <year>2013</year>; <volume>155</volume>:<fpage>934</fpage>–<lpage>947</lpage>.<pub-id pub-id-type="pmid">24119843</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>F.W.</given-names></string-name>, <string-name><surname>Jane-Valbuena</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kryukov</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>E.R.</given-names></string-name>, <string-name><surname>Barretina</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gelfand</surname><given-names>E.T.</given-names></string-name>, <string-name><surname>Bielski</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Next-generation characterization of the Cancer Cell Line Encyclopedia</article-title>. <source>Nature</source>. <year>2019</year>; <volume>569</volume>:<fpage>503</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research, N.</collab><string-name><surname>Weinstein</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Collisson</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Mills</surname><given-names>G.B.</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>K.R.</given-names></string-name>, <string-name><surname>Ozenberger</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Ellrott</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shmulevich</surname><given-names>I.</given-names></string-name>, <string-name><surname>Sander</surname><given-names>C.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>J.M</given-names></string-name></person-group><article-title>The cancer genome atlas pan-cancer analysis project</article-title>. <source>Nat. Genet.</source><year>2013</year>; <volume>45</volume>:<fpage>1113</fpage>–<lpage>1120</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>H.</given-names></string-name></person-group><article-title>A high-resolution map of Human enhancer RNA loci characterizes super-enhancer activities in cancer</article-title>. <source>Cancer Cell</source>. <year>2020</year>; <volume>38</volume>:<fpage>701</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">33007258</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tate</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Bamford</surname><given-names>S.</given-names></string-name>, <string-name><surname>Jubb</surname><given-names>H.C.</given-names></string-name>, <string-name><surname>Sondka</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Beare</surname><given-names>D.M.</given-names></string-name>, <string-name><surname>Bindal</surname><given-names>N.</given-names></string-name>, <string-name><surname>Boutselakis</surname><given-names>H.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Creatore</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dawson</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>COSMIC: the catalogue of somatic mutations In cancer</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D941</fpage>–<lpage>D947</lpage>.<pub-id pub-id-type="pmid">30371878</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Song</surname><given-names>C.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ning</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>KnockTF: a comprehensive human gene expression profile database with knockdown/knockout of transcription factors</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D93</fpage>–<lpage>D100</lpage>.<pub-id pub-id-type="pmid">31598675</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rees</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Seashore-Ludlow</surname><given-names>B.</given-names></string-name>, <string-name><surname>Cheah</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Price</surname><given-names>E.V.</given-names></string-name>, <string-name><surname>Gill</surname><given-names>S.</given-names></string-name>, <string-name><surname>Javaid</surname><given-names>S.</given-names></string-name>, <string-name><surname>Coletti</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>V.L.</given-names></string-name>, <string-name><surname>Bodycombe</surname><given-names>N.E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</article-title>. <source>Nat. Chem. Biol.</source><year>2016</year>; <volume>12</volume>:<fpage>109</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">26656090</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Soares</surname><given-names>J.</given-names></string-name>, <string-name><surname>Greninger</surname><given-names>P.</given-names></string-name>, <string-name><surname>Edelman</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Lightfoot</surname><given-names>H.</given-names></string-name>, <string-name><surname>Forbes</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bindal</surname><given-names>N.</given-names></string-name>, <string-name><surname>Beare</surname><given-names>D.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>I.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D955</fpage>–<lpage>D961</lpage>.<pub-id pub-id-type="pmid">23180760</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name></person-group><article-title>Fast and accurate long-read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>. <year>2010</year>; <volume>26</volume>:<fpage>589</fpage>–<lpage>595</lpage>.<pub-id pub-id-type="pmid">20080505</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Handsaker</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wysoker</surname><given-names>A.</given-names></string-name>, <string-name><surname>Fennell</surname><given-names>T.</given-names></string-name>, <string-name><surname>Ruan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Homer</surname><given-names>N.</given-names></string-name>, <string-name><surname>Marth</surname><given-names>G.</given-names></string-name>, <string-name><surname>Abecasis</surname><given-names>G.</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name><collab>Genome Project Data Processing, S</collab></person-group><article-title>The sequence alignment/map format and SAMtools</article-title>. <source>Bioinformatics</source>. <year>2009</year>; <volume>25</volume>:<fpage>2078</fpage>–<lpage>2079</lpage>.<pub-id pub-id-type="pmid">19505943</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quinlan</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>I.M.</given-names></string-name></person-group><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title>. <source>Bioinformatics</source>. <year>2010</year>; <volume>26</volume>:<fpage>841</fpage>–<lpage>842</lpage>.<pub-id pub-id-type="pmid">20110278</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>T.</given-names></string-name></person-group><article-title>Use model-based analysis of ChIP-Seq (MACS) to analyze short reads generated by sequencing protein-DNA interactions in embryonic stem cells</article-title>. <source>Methods Mol. Biol.</source><year>2014</year>; <volume>1150</volume>:<fpage>81</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">24743991</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>D.</given-names></string-name>, <string-name><surname>Langmead</surname><given-names>B.</given-names></string-name>, <string-name><surname>Salzberg</surname><given-names>S.L.</given-names></string-name></person-group><article-title>HISAT: a fast spliced aligner with low memory requirements</article-title>. <source>Nat. Methods</source>. <year>2015</year>; <volume>12</volume>:<fpage>357</fpage>–<lpage>360</lpage>.<pub-id pub-id-type="pmid">25751142</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anders</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pyl</surname><given-names>P.T.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name></person-group><article-title>HTSeq–a Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source>. <year>2015</year>; <volume>31</volume>:<fpage>166</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">25260700</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name>, <string-name><surname>Anders</surname><given-names>S.</given-names></string-name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ross-Innes</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Stark</surname><given-names>R.</given-names></string-name>, <string-name><surname>Teschendorff</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Ali</surname><given-names>H.R.</given-names></string-name>, <string-name><surname>Dunning</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>G.D.</given-names></string-name>, <string-name><surname>Gojis</surname><given-names>O.</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>I.O.</given-names></string-name>, <string-name><surname>Green</surname><given-names>A.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Differential oestrogen receptor binding is associated with clinical outcome in breast cancer</article-title>. <source>Nature</source>. <year>2012</year>; <volume>481</volume>:<fpage>389</fpage>–<lpage>393</lpage>.<pub-id pub-id-type="pmid">22217937</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heinz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Benner</surname><given-names>C.</given-names></string-name>, <string-name><surname>Spann</surname><given-names>N.</given-names></string-name>, <string-name><surname>Bertolino</surname><given-names>E.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y.C.</given-names></string-name>, <string-name><surname>Laslo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>J.X.</given-names></string-name>, <string-name><surname>Murre</surname><given-names>C.</given-names></string-name>, <string-name><surname>Singh</surname><given-names>H.</given-names></string-name>, <string-name><surname>Glass</surname><given-names>C.K.</given-names></string-name></person-group><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title>. <source>Mol. Cell</source>. <year>2010</year>; <volume>38</volume>:<fpage>576</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">20513432</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maeser</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gruener</surname><given-names>R.F.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>R.S.</given-names></string-name></person-group><article-title>oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data</article-title>. <source>Brief Bioinform.</source><year>2021</year>; <volume>22</volume>:<fpage>bbab260</fpage>.<pub-id pub-id-type="pmid">34260682</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheffield</surname><given-names>N.C.</given-names></string-name>, <string-name><surname>Bock</surname><given-names>C.</given-names></string-name></person-group><article-title>LOLA: enrichment analysis for genomic region sets and regulatory elements in R and bioconductor</article-title>. <source>Bioinformatics</source>. <year>2016</year>; <volume>32</volume>:<fpage>587</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">26508757</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>X.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.S.</given-names></string-name></person-group><article-title>Cistrome-GO: a web server for functional enrichment analysis of transcription factor ChIP-seq peaks</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>W206</fpage>–<lpage>W211</lpage>.<pub-id pub-id-type="pmid">31053864</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>W.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>J.</given-names></string-name></person-group><article-title>The role of hepatocyte nuclear factor 4alpha (HNF4alpha) in tumorigenesis</article-title>. <source>Front. Oncol.</source><year>2022</year>; <volume>12</volume>:<fpage>1011230</fpage>.<pub-id pub-id-type="pmid">36249028</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ballian</surname><given-names>N.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Brunicardi</surname><given-names>F.C.</given-names></string-name></person-group><article-title>Transcription factor PDX-1 in human colorectal adenocarcinoma: a potential tumor marker?</article-title>. <source>World J. Gastroenterol.</source><year>2008</year>; <volume>14</volume>:<fpage>5823</fpage>–<lpage>5826</lpage>.<pub-id pub-id-type="pmid">18855980</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Masuda</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bartholomeusz</surname><given-names>C.</given-names></string-name>, <string-name><surname>Doihara</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hortobagyi</surname><given-names>G.N.</given-names></string-name>, <string-name><surname>Ueno</surname><given-names>N.T.</given-names></string-name></person-group><article-title>Role of epidermal growth factor receptor in breast cancer</article-title>. <source>Breast Cancer Res. Treat.</source><year>2012</year>; <volume>136</volume>:<fpage>331</fpage>–<lpage>345</lpage>.<pub-id pub-id-type="pmid">23073759</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id>
    <journal-id journal-id-type="publisher-id">narcancer</journal-id>
    <journal-title-group>
      <journal-title>NAR Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2632-8674</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10782923</article-id>
    <article-id pub-id-type="doi">10.1093/narcan/zcad063</article-id>
    <article-id pub-id-type="publisher-id">zcad063</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00030</subject>
        <subject>AcademicSubjects/SCI00980</subject>
        <subject>AcademicSubjects/SCI01060</subject>
        <subject>AcademicSubjects/SCI01140</subject>
        <subject>AcademicSubjects/SCI01180</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Cancer Data Resource</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>TSCRE: a comprehensive database for tumor-specific <italic toggle="yes">cis</italic>-regulatory elements</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Peng</surname>
          <given-names>Guanjie</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Bingyuan</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zheng</surname>
          <given-names>Mohan</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Luowanyue</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Huiqin</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Mengni</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liang</surname>
          <given-names>Yuan</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Tianjian</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Luo</surname>
          <given-names>Xiaotong</given-names>
        </name>
        <aff><institution>Guangdong Institute of Gastroenterology, Department of General Surgery</institution>, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5774-8568</contrib-id>
        <name>
          <surname>Shi</surname>
          <given-names>Xianping</given-names>
        </name>
        <!--xianping.shi@gzhmu.edu.cn-->
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4161-1292</contrib-id>
        <name>
          <surname>Ren</surname>
          <given-names>Jian</given-names>
        </name>
        <!--renjian@sysucc.org.cn-->
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5692-8903</contrib-id>
        <name>
          <surname>Zheng</surname>
          <given-names>Yueyuan</given-names>
        </name>
        <!--zhengyy86@mail.sysu.edu.cn-->
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 13509645425; Email: <email>zhengyy86@mail.sysu.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Jian Ren. Tel: +86 13751761881; Email: <email>renjian@sysucc.org.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Xianping Shi. Tel: +86 13570066303; Email: <email>xianping.shi@gzhmu.edu.cn</email></corresp>
      <fn id="FN1">
        <p>The first four authors should be regarded as joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-01-11">
      <day>11</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>11</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <volume>6</volume>
    <issue>1</issue>
    <elocation-id>zcad063</elocation-id>
    <history>
      <date date-type="accepted">
        <day>31</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>18</day>
        <month>11</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>28</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of NAR Cancer.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="zcad063.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p><italic toggle="yes">Cis</italic>-regulatory elements (CREs) and super <italic toggle="yes">cis-</italic>regulatory elements (SCREs) are non-coding DNA regions which influence the transcription of nearby genes and play critical roles in development. Dysregulated CRE and SCRE activities have been reported to alter the expression of oncogenes and tumor suppressors, thereby regulating cancer hallmarks. To address the strong need for a comprehensive catalogue of dysregulated CREs and SCREs in human cancers, we present TSCRE (<ext-link xlink:href="http://tscre.zsqylab.com/" ext-link-type="uri">http://tscre.zsqylab.com/</ext-link>), an open resource providing tumor-specific and cell type-specific CREs and SCREs derived from the re-analysis of publicly available histone modification profiles. Currently, TSCRE contains 1 864 941 dysregulated CREs and 68 253 dysregulated SCREs identified from 1366 human patient samples spanning 17 different cancer types and 9 histone marks. Over 95% of these elements have been validated in public resources. TSCRE offers comprehensive annotations for each element, including associated genes, expression patterns, clinical prognosis, somatic mutations, transcript factor binding sites, cancer-type specificity, and drug response. Additionally, TSCRE integrates pathway and transcript factor enrichment analyses for each study, enabling in-depth functional and mechanistic investigations. Furthermore, TSCRE provides an interactive interface for users to explore any CRE and SCRE of interest. We believe TSCRE will be a highly valuable platform for the community to discover candidate cancer biomarkers.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="zcad063figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32200538</award-id>
        <award-id>32200542</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Shenzhen Science and Technology Innovation Commission</institution>
            <institution-id institution-id-type="DOI">10.13039/501100010877</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>JCYJ20220530144815036</award-id>
        <award-id>JCYJ20230807110309019</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Guangdong Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003453</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2021A1515011334</award-id>
        <award-id>2023A1515011976</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>82170177/H0809</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Sun Yat-sen University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100002402</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>ZSQYBRJH0025</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p><italic toggle="yes">Cis</italic>-regulatory elements (CREs), including enhancers, promoters, and silencers, are crucial for controlling gene expression during development (<xref rid="B1" ref-type="bibr">1–3</xref>). Super <italic toggle="yes">cis-</italic>regulatory elements (SCREs), characterized by large clusters of regulatory regions, are essential in determining cell differentiation and identity (<xref rid="B4" ref-type="bibr">4–6</xref>). Numerous CREs and SCREs have been identified across human tissues and diseases. In the context of human cancers, the aberrant activity of CREs and SCREs can lead to the dysregulation of oncogenes and tumor suppressors, disrupting normal cellular processes and promoting cancer hallmarks such as proliferation, invasion and metastasis (<xref rid="B7" ref-type="bibr">7–9</xref>). Dysregulations in enhancers, super-enhancers, silencers, and promoters are common epigenetic alterations. For example, aberrant regulation of enhancers and super-enhancers have been frequently observed in various cancers, resulting in the upregulation of key oncogenes, such as <italic toggle="yes">MYC</italic> and <italic toggle="yes">FOXQ1</italic> in colorectal cancer (<xref rid="B10" ref-type="bibr">10</xref>), as well as <italic toggle="yes">FOXC1</italic> and <italic toggle="yes">MET</italic> in triple-negative breast cancer (<xref rid="B11" ref-type="bibr">11</xref>). Additionally, many silencers, characterized by extensive broad H3K27me3 modification, exhibit a significant reduction in H3K27me3 modification size in human tumors, thereby promoting the activation of oncogenes such as <italic toggle="yes">MYH11</italic> and <italic toggle="yes">EGFR</italic> (<xref rid="B12" ref-type="bibr">12</xref>). Moreover, dysregulation of promoters, including promoter hypermethylation and alterations in H3K4me3 along with H3K27ac, is frequently observed in cancer (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>). These dysregulations of CREs and SCREs exhibit specificity towards particular cancer types or subtypes, reflecting the unique epigenomic landscapes of different cells and tumors (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>). Recent studies have highlighted the potential of dysregulated CREs and SCREs as promising targets for cancer diagnosis and treatment (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). For instance, the exclusive activity of the <italic toggle="yes">INSM1</italic> promoter in insulinoma tumors has been leveraged for adenoviral therapy in insulinoma treatment (<xref rid="B19" ref-type="bibr">19</xref>). Therefore, the accumulating evidence for the essential roles of dysregulated CREs and SCREs in cancer biology, emphasizes the urgent need to comprehensively catalog dysregulated CREs and SCREs across various human cancer types.</p>
    <p>Previous studies have demonstrated the efficiency and robustness of histone modification profiling in identifying distinct classes of regulatory elements (<xref rid="B20" ref-type="bibr">20–22</xref>). For example, promoters can be identified by the histone mark H3K4me3, enhancers by H3K4me1, active regulatory elements by H3K27ac, and repressive elements by either H3K27me3 or H3K9me3 (<xref rid="B18" ref-type="bibr">18</xref>). With the rapid accumulation of chromatin immunoprecipitation sequencing (ChIP-seq) data on histone marks, several CRE and SCRE databases have been developed, such as ENCODE (<xref rid="B23" ref-type="bibr">23</xref>), CistromeDB (<xref rid="B24" ref-type="bibr">24</xref>), ChIP-Atlas (<xref rid="B25" ref-type="bibr">25</xref>), SEdb v2.0 (<xref rid="B26" ref-type="bibr">26</xref>), SEA v3.0 (<xref rid="B27" ref-type="bibr">27</xref>) and dbSUPER (<xref rid="B28" ref-type="bibr">28</xref>). These databases serve as valuable resources for investigating <italic toggle="yes">cis-</italic>regulatory elements, but they primarily focus on profiling of CREs or SCREs within individual tissues and cells. There is an urgent need for the collection of feature-specific dysregulated elements in human cancers (e.g. tumor-specific, metastasis-specific, and subtype-specific elements). Additionally, besides super-enhancers, other broad regulatory elements, such as super repressive elements and broad H3K4me3 regions, have also been implicated in cancer (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>), emphasizing the importance of their efficient identification and characterization. Moreover, further research on dysregulated CREs and SCREs heavily relies on reliable regulatory annotation, including genetic and epigenetic annotation, as well as association analyses involving transcription factors, cancer pathways, clinical prognosis, and response to anticancer drugs. Therefore, it is necessary to develop a comprehensive database dedicated to cancer-associated CREs and SCREs, elucidating their regulatory mechanisms in a highly cancer-specific context.</p>
    <p>Here, we present TSCRE (<ext-link xlink:href="http://tscre.zsqylab.com/" ext-link-type="uri">http://tscre.zsqylab.com/</ext-link>), a comprehensive open resource of tumor-specific and cell type-specific CREs and SCREs derived through extensive re-analyses of public histone modification profiling data in human cancers (Figure <xref rid="F1" ref-type="fig">1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). Using TSCRE, users are able to efficiently and intuitively explore dysregulated CREs or SCREs of interest in various cancer types of contrast experiments, such as ‘tumor vs. nonmalignant’, ‘metastasis vs. primary’, "mutant vs. wildtype’. We believe this platform will greatly benefit the research community by aiding in the screening of candidate CREs and SCREs, as well as facilitating the identification of relevant transcriptional regulators in human cancers.</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Overall design and construction of TSCRE.</p>
      </caption>
      <graphic xlink:href="zcad063fig1" position="float"/>
    </fig>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection</title>
      <p>A systematic search was conducted to find out cancer-associated histone modification profiles. Firstly, the GEO and SRA database were searched using keywords relating to nine of better-known histone markers (including H3K27ac, H3K4me3, H3K4me2, H3K4me1, H3K36me3, H3K9ac, H3K79me2, H3K9me3 and H3K27me3), along with the term ‘Genome binding/occupancy profiling by high throughput sequencing’. Datasets were restricted to human studies published before February 2023. Then we performed a manual screening and reserved studies that met the following criteria: 1) inclusion of tumor tissue or cancer cell lines, 2) samples in each study that could be compared based on a specific biological condition, including ‘tumor vs. non-malignant,’ ‘metastasis vs. primary,’ ‘mutant vs. wild-type’ or ‘subtype1 vs. subtype2’ and 3) presence of at least two biological replicates for each condition. In addition, matched RNA-seq data from the corresponding studies were downloaded when available.</p>
      <p>The following additional datasets were collected: long-range interactions between genes and distal regulatory regions, including pan-cancer ‘enhancer-to-gene’ links from TCGA ATAC-seq projects (<xref rid="B29" ref-type="bibr">29</xref>), Hi-C loops from 3D Genome Browser (<xref rid="B30" ref-type="bibr">30</xref>), and HiChIP loops from matched studies. Other <italic toggle="yes">cis-</italic>regulatory elements were obtained from public resources, containing DNase I-hypersensitive sites (DHSs) from the ENCODE project (<xref rid="B23" ref-type="bibr">23</xref>), CREs from the FANTOM5 project (<xref rid="B31" ref-type="bibr">31</xref>), enhancers from GeneHancer (<xref rid="B32" ref-type="bibr">32</xref>), silencers from SilencerDB (<xref rid="B33" ref-type="bibr">33</xref>) and super-enhancers from a recent publication (<xref rid="B34" ref-type="bibr">34</xref>). Multi-omics data of pan-cancer tissues and cell lines were extracted from TCGA and DepMap projects, containing mRNA expression, somatic mutations, chromatin accessibility, clinical data and CRISPR scores (<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>). In addition, we also obtained enhancer RNA (eRNA) expression from the TCeA Portal and mutations from COSMIC (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>). TFBSs from the ENCODE project and TF target genes from KnockTF were also included in our database (<xref rid="B39" ref-type="bibr">39</xref>). Lastly, we acquired pharmacogenomic data from GDSC2 and CTRP2, which involved drug response data from 198 and 545 compounds in various cancer lineages (<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Data preprocessing</title>
      <p>Raw ChIP-seq reads were trimmed using Trim-galore (version 0.6.6) and then aligned to the GRCh38 genome (ENSEMBL release 84) using BWA (version 0.7.17) with default parameters (<xref rid="B42" ref-type="bibr">42</xref>). Then uniquely mapped reads were extracted and sorted using SAMtools (version 1.7) program with the ‘-q 1’ option (<xref rid="B43" ref-type="bibr">43</xref>). PCR duplicates were removed using the Picard MarkDuplicates tool (version 2.26.2), and ENCODE blacklist regions were excluded using BEDtools (version v2.26.0) (<xref rid="B44" ref-type="bibr">44</xref>). MACS2 (Model-Based Analysis of ChIP-Seq, version 2.2.6) was applied to call peaks (refer to CREs) with the options ‘-q 0.01 –extsize = 146 –nomodel’ (<xref rid="B45" ref-type="bibr">45</xref>). Samples meeting all the following criteria are retained for further analysis: (i) duplication rates &lt;0.5; (ii) mapping rates &gt;0.6; (iii) at least 5 million usable fragments for narrow marks and 15 million for broad marks; (iv) peaks &gt;500 and fraction of reads in peaks (FRiP) ≥1%.</p>
      <p>Similarly, raw RNA-seq reads were processed to remove low-quality reads using Trim-galore (version 0.6.6) with default parameters. High-quality reads were then aligned to the GRCh38 genome using HISAT2 (version 7.2.0) and gene quantification was performed using the htseq-count program (version 0.11.3) with default settings (<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). Samples with a mapping rate &gt;0.6 and at least 10 million usable fragments were selected for differential gene expression analysis. The DESeq2 package or Wilcoxon test (≥8 samples in each given condition) were applied to identify differentially expressed genes, employing the criteria of ‘adjusted <italic toggle="yes">P</italic>-value &lt;0.05 and absolute fold-change &gt;1.5’ (<xref rid="B48" ref-type="bibr">48</xref>).</p>
    </sec>
    <sec id="SEC2-3">
      <title>Dysregulated CRE/SCRE identification</title>
      <p>Peaks modified by different histone markers, as identified in the previous section, were considered as CREs. DiffBind (version 3.6.5) was then used to compare CREs between two conditions and those with a fold change ≥1.5 and FDR &lt;0.05 were selected as dysregulated CREs (<xref rid="B49" ref-type="bibr">49</xref>).</p>
      <p>Among SCREs, the most extensively studied subset are super-enhancers, usually marked by H3K27ac modification. Rank Order of Super Enhancers (ROSE) is a commonly used method for identifying super-enhancers (<xref rid="B5" ref-type="bibr">5</xref>). Briefly, ROSE merged enhancer elements within a 12.5-kb distance and arranges them in decreasing order of intensities. Super-enhancers are then defined as stitching elements exhibiting a tangent slope with an inflection point value ≥1. ROSE (version 1.0) was also applied to identify super repressive elements enriched with H3K27me3 modification (<xref rid="B6" ref-type="bibr">6</xref>). Considering the potential variations in the stitching distance for different histone marks, we initially determined the most suitable distance for each histone mark by analyzing the histone modification peaks across various cell types from the ENCODE project. We merged peaks within different stitching distances for each dataset, ranging from 0.5 to 24 kb with 0.5 kb increments, and identified SCREs at each distance. We then counted the total number of peaks contained in SCREs and selected the optimal distance when the increasing number at that distance stabilized compared to the previous distance. As shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>, H3K27ac and H3K27me3 peaks within SCREs reached stability at 12 and 5 kb, respectively, which were close to the reported values of 12.5 and 4 kb. After obtaining the optimal distance for each histone marker (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>), we used ROSE to identify SCREs for each sample. Next, we employed the BEDtools multiinter function to find a consensus SCRE set of unique genomic intervals presenting in at least two samples for each study. Finally, DiffBind program was applied to identify the dysregulated SCREs and those with a fold change ≥1.5 and <italic toggle="yes">P</italic> value &lt;0.05 were selected.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Annotations of dysregulated CRE/SCREs</title>
      <p>We validated the accuracy of CREs and SCREs by checking whether they overlapped with regulatory regions obtained from ENCODE, FANTOM5, GeneHancer, SilencerDB and other existing literature (<xref rid="B34" ref-type="bibr">34</xref>). We then applied three gene annotation strategies to find the associated genes for each element. First, we mapped CREs to the nearest genes using the Homer annotatePeaks.pl function (<xref rid="B50" ref-type="bibr">50</xref>), while mapping SCREs to the nearest or overlapping genes with the help of ROSE_geneMapper.py function. Second, we associated distal CREs and SCREs with ATAC-seq-linked genes, which were established by the TCGA consortium based on the correlation between ATAC-Seq peaks and the expression levels of neighboring genes. Lastly, we assigned distal CREs and SCREs to their respective genes using Hi-C and HiChIP loops. To assist researchers in identifying the most relevant regulatory genes, we calculated mRNA expression level for each associated gene from available matched samples, pan-cancer tissues as well as cancer cell lines, and examine the survival outcome in cancer samples. Furthermore, associated TFBSs and somatic mutations were assigned to each CRE and SCRE using the BEDTools intersect program.</p>
    </sec>
    <sec id="SEC2-5">
      <title>Assessing cancer-type specificity and examining associations with drug response</title>
      <p>The cancer-type specificity of each regulatory element was determined by calculating its overlap with other elements in TSCRE, as well as by assessing the chromatin accessibility and enhancer RNA activity in the TCGA pan-cancer landscape. Additionally, we employed calcPhenotype function from the oncoPredict package to impute the drug response from GDSC and CTRP cancer cell lines to TCGA patient samples, after which we calculated the associations of each regulatory element with the imputed drug response (<xref rid="B51" ref-type="bibr">51</xref>). To achieve this, we trained linear ridge regression models using the expression levels and drug sensitivity scores of the cancer cell lines from GDSC and CTRP. These models were then applied to the expression levels of TCGA samples, generating predicted scores for drug sensitivity for each TCGA patient. Next, we evaluated the accessibility of each regulatory element in the corresponding TCGA patients using TCGA ATAC-seq signals, and further determined the associations between regulatory element accessibility and imputed drug response using Spearman correlation. Associations with |<italic toggle="yes">R</italic>| &gt;0.3 and FDR &lt;0.05 were considered as significant associations in each cancer type.</p>
    </sec>
    <sec id="SEC2-6">
      <title>Identification of enriched TFs and biological functions</title>
      <p>Enrichment analysis of TF binding sites was conducted for dysregulated elements using the Homer findMotifs.pl function and LOLA program, setting one condition's dysregulated CRE/SCREs as the foreground and the other's as the background (<xref rid="B52" ref-type="bibr">52</xref>). To gain a deeper understanding of the context specificity and essentiality of each significant TF (FDR &lt; 0.01), we analyzed their corresponding expression levels in TCGA pan-cancer samples, gene dependency scores in cancer cell lines, and clinical prognosis. Furthermore, we introduced the KnockTF datasets and presented the potential downstream targets.</p>
      <p>For biological functions, we employed the solo mode of Cistrome-GO program to perform pathway enrichment analysis by using the collections of gene sets from KEGG and GO-BP (<xref rid="B53" ref-type="bibr">53</xref>). A minimum-hypergeometric test was conducted to identify the enriched pathways with an FDR &lt; 0.2. The detailed information about association analyses were listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>.</p>
    </sec>
    <sec id="SEC2-7">
      <title>Identification of tumor-specific and cell type-specific CREs and SCREs</title>
      <p>To identify more CREs and SCREs that regulate oncogenes in tumor-specific and cell type-specific manners, we first selected the CREs and SCREs that demonstrated gained active modification or lost repressive modification in tumor samples compared with nonmalignant samples. We then employed a prioritization approach to select the most promising candidates from all association analyses based on the specific criteria. These criteria included: (i) enhanced expression of the associated gene, (ii) ranking within the top 5 for chromatin accessibility, (iii) ranking within the top 5 for eRNA activity and (iv) exhibiting an overlap of at least 50% in length with fewer than two <italic toggle="yes">cis-</italic>regulatory elements found in other cancer types. CREs and SCREs that met all these criteria were considered to have a high confidence level of tumor specificity and cancer-type specificity. Additionally, CREs and SCREs that satisfied three criteria achieved a median confidence level. Furthermore, CREs and SCREs that met two criteria were regarded as having a low confidence level.</p>
    </sec>
    <sec id="SEC2-8">
      <title>Web interface implementation</title>
      <p>All the metadata and analysis results were stored and managed using MySQL tables. The web interfaces were implemented using Hyper Text Markup Language (HTML), Cascading Style Sheets (CSS), and JavaScript (JS). To visualize all the analysis results, various statistical diagrams were shown by EChars and UCSC Genome Browser were implemented.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Data summary</title>
      <p>In the current release, TSCRE contains 138 carefully curated histone ChIP-seq datasets covering 1366 patient samples across 9 different histone marks and 17 different cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). Of these, 1034 samples were collected from patient tissues, while 332 samples were derived from cancer cell lines (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1C</xref>). Across 17 cancer types, a total of 18 64 941 dysregulated CREs and 68 253 dysregulated SCREs were identified in one of the following conditions: ‘tumor versus nonmalignant’, ‘metastasis versus primary’, ‘mutant versus wildtype’ and ‘subtype1 versus subtype2’ (Table <xref rid="tbl1" ref-type="table">1</xref>). Notably, approximately 95% of CREs and 99% of SCREs have been validated in at least one public resource, demonstrating the reproducibility and robustness of our data analyses.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>Statistics of dysregulated CREs and SCREs in TSCRE</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th colspan="2" align="center" rowspan="1">Tumor versus nonmalignant</th>
              <th colspan="2" align="center" rowspan="1">Metastasis versus primary</th>
              <th colspan="2" align="center" rowspan="1">Mutant versus wildtype</th>
              <th colspan="2" align="center" rowspan="1">Subtype1 versus Subtype2</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1">
                <inline-graphic xlink:href="zcad063figu1.jpg"/>
              </th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Colorectal cancer</td>
              <td rowspan="1" colspan="1">143 662</td>
              <td rowspan="1" colspan="1">4878</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Uterine leiomyoma</td>
              <td rowspan="1" colspan="1">68 805</td>
              <td rowspan="1" colspan="1">2481</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Gastric cancer</td>
              <td rowspan="1" colspan="1">58 686</td>
              <td rowspan="1" colspan="1">2339</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Prostate cancer</td>
              <td rowspan="1" colspan="1">40 833</td>
              <td rowspan="1" colspan="1">2422</td>
              <td rowspan="1" colspan="1">68805</td>
              <td rowspan="1" colspan="1">2170</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Liver cancer</td>
              <td rowspan="1" colspan="1">32 847</td>
              <td rowspan="1" colspan="1">1187</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kidney cancer</td>
              <td rowspan="1" colspan="1">32 209</td>
              <td rowspan="1" colspan="1">3000</td>
              <td rowspan="1" colspan="1">8</td>
              <td rowspan="1" colspan="1">98</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">341 735</td>
              <td rowspan="1" colspan="1">8502</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Glioma</td>
              <td rowspan="1" colspan="1">18 657</td>
              <td rowspan="1" colspan="1">1481</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Esophageal cancer</td>
              <td rowspan="1" colspan="1">7841</td>
              <td rowspan="1" colspan="1">442</td>
              <td rowspan="1" colspan="1">2145</td>
              <td rowspan="1" colspan="1">172</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">20 562</td>
              <td rowspan="1" colspan="1">560</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Follicular lymphoma</td>
              <td rowspan="1" colspan="1">257</td>
              <td rowspan="1" colspan="1">170</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Diffuse large B cell lymphoma</td>
              <td rowspan="1" colspan="1">339</td>
              <td rowspan="1" colspan="1">82</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Natural killer T-cell lymphoma</td>
              <td rowspan="1" colspan="1">27 784</td>
              <td rowspan="1" colspan="1">713</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lung cancer</td>
              <td rowspan="1" colspan="1">25 066</td>
              <td rowspan="1" colspan="1">1584</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Breast cancer</td>
              <td rowspan="1" colspan="1">543 577</td>
              <td rowspan="1" colspan="1">17 615</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">296 088</td>
              <td rowspan="1" colspan="1">11 537</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Head and neck cancer</td>
              <td rowspan="1" colspan="1">51 649</td>
              <td rowspan="1" colspan="1">3276</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">9796</td>
              <td rowspan="1" colspan="1">1052</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pancreatic cancer</td>
              <td rowspan="1" colspan="1">7198</td>
              <td rowspan="1" colspan="1">81</td>
              <td rowspan="1" colspan="1">59 098</td>
              <td rowspan="1" colspan="1">1669</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Osteosarcoma</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">193</td>
              <td rowspan="1" colspan="1">207</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Chronic lymphocytic leukemia</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">7101</td>
              <td rowspan="1" colspan="1">535</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Total</td>
              <td rowspan="1" colspan="1">1 059 410</td>
              <td rowspan="1" colspan="1">41 751</td>
              <td rowspan="1" colspan="1">130 249</td>
              <td rowspan="1" colspan="1">4316</td>
              <td rowspan="1" colspan="1">7101</td>
              <td rowspan="1" colspan="1">535</td>
              <td rowspan="1" colspan="1">668 181</td>
              <td rowspan="1" colspan="1">21651</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To facilitate further functional and mechanistic studies, systematic association analyses are integrated into TSCRE. First, we provide detailed gene annotation, associated TFBSs and somatic mutations for each dysregulated element. In addition to the nearest or overlapping genes, a total of 220 681 distal CREs and 44 639 distal SCREs were associated with specific genes through distal element-to-promoter loops. Additionally, 80.09% (1 493 595/1 864 941) of CREs and 99.96% (68 224/68 253) of SCREs exhibited one or more TFBSs. Moreover, 31 705 dysregulated CREs and 27 029 dysregulated SCREs had associated somatic mutations in the corresponding cancer type. These findings highlight the importance of <italic toggle="yes">cis-</italic>regulatory elements in addressing key issues related to cancer biology. Second, we accessed the cancer-type specificity of each regulatory element. Notably, a large proportion of CREs (83.8%) and SCREs (59.58%) show overlap with other regulatory elements in three or fewer cancer types, indicating a high degree of cancer-type specificity (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>). Third, we assessed the association between regulatory elements and imputed drug response in patients across various cancer types, providing a more direct and powerful evaluation of the role of CREs and SCREs in targeted therapy compared to <italic toggle="yes">in vitro</italic> cell lines. We obtained 20 812 864 associations between CRE accessibility and the imputed drug response, consisting of 6 531 763 associations detected from CTRP and 14 281 101 associations from GDSC. Similarly, 672 248 associations were found in SCREs. These data provide valuable insights into the potential impact of regulatory elements on drug response in cancer patients. The dysregulation of CRE and SCREs can influence transcriptional programs by facilitating or restricting the accessibility of transcript factor binding sites in a tumor-specific and cell type-specific manner, thereby mediating the activation of cancer-associated pathways. We further identified all enriched TFs and pathways for each study to promote follow-up functional and mechanistic studies. Additionally, we collected a comprehensive dataset comprising 683 TF knockout microarrays and RNA-seq data from the KnockTF database, enabling the identification of potential downstream targets.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Data access</title>
      <p>TSCRE provides a user-friendly web interface, allowing users to intuitively explore and search any CRE or SCRE:</p>
      <p><bold>Explore</bold>. Users can select the cancer type(s), histone marker(s) and condition(s) of interest either through an interactive heatmap or a summary list. For example, if users are interested in studying tumor-specific regulatory elements in colorectal cancer, they can easily choose ‘colorectal cancer’ and ‘Tumor vs Nonmalignant’ from the metadata selection facet (Figure <xref rid="F2" ref-type="fig">2A</xref>). Subsequently, the relevant heatmap cells are retrieved (Figure <xref rid="F2" ref-type="fig">2A</xref>), and upon clicking on a specific cell, a dataset list is presented (Figure <xref rid="F2" ref-type="fig">2B</xref>). Data in TSCRE is organized into two layers: CRE and SCRE. By clicking on ‘CRE’ or ‘SCRE’ in a dataset of interest, users will be directed to a detailed page that provides study and sample details, CRE/SCRE information, as well as TF and pathway enrichment analysis. The CRE/SCRE information section shows all dysregulated elements and summarizes the number of association analyses conducted for each element (Figure <xref rid="F2" ref-type="fig">2C</xref>). Clicking on individual CRE ID shows the detailed information for each dysregulated element. The TF enrichment analysis section displays significantly enriched TFs identified in this study (Figure <xref rid="F2" ref-type="fig">2D</xref>). Some visualized figures are generated in real time to allow investigation of the cancer-type specificity and potential targets of enriched TFs (Figure <xref rid="F2" ref-type="fig">2E</xref>). For instance, HNF4A, a well-established gastrointestinal-specific transcription factor (<xref rid="B54" ref-type="bibr">54</xref>), ranked as the second most enriched TF in colorectal cancer-specific CREs (Figure <xref rid="F2" ref-type="fig">2D</xref>). HNF4A exhibited the highest expression levels in both colorectal cancer tissues and cell lines, regulated many target genes and was essential for the viability of the majority of colorectal cancer cells in the unbiased high-throughput CRISPR screening (Figure <xref rid="F2" ref-type="fig">2E</xref>). The pathway enrichment analysis section displays all enriched pathways associated with dysregulated elements and the top 10 pathways are shown in a bubble plot.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>A schematic workflow of the browse interface in TSCRE. <bold>(A)</bold> TSCRE provides an interactive heatmap and a summary list to browse and select studies of interest. Snapshot of results for colorectal cancer in ‘Tumor vs Nonmalignant’ condition. <bold>(B)</bold> A summary list is shown when clicking on a specific heatmap cell. Data in TSCRE is organized into two layers: CRE and SCRE. <bold>(C)</bold> The CRE information section shows all dysregulated elements and summarizes the number of association analyses conducted for each element. <bold>(D)</bold> Snapshot of HNF4A as the second most enriched TF. <bold>(E)</bold> Click the ‘eye’ button to get the expression levels of HNF4A in pan-cancer tissues and cell lines, the gene dependency scores, as well as potential target genes.</p>
        </caption>
        <graphic xlink:href="zcad063fig2" position="float"/>
      </fig>
      <p><bold>Search</bold>. TSCRE provides three modes to query the database, according to your interest in specific genes, transcription factors, and genomic regions. All the search results are summarized with real-time statistical diagrams and further filtered by check boxes.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Tumor-specific CREs and SCREs identified in TSCRE</title>
      <p>TSCRE is a valuable resource to explore and discover cancer biomarkers. Through the analysis of the ‘Tumor vs Nonmalignant’ comparison, we identified 918 CREs and 405 SCREs that exhibited a high confidence level of tumor specificity and cancer-type specificity (see Materials and methods). Additionally, 24 821 CREs and 1948 SCREs met the criteria for the median confidence level. Furthermore, we identified 151 273 CREs and 3880 SCREs with a low confidence level (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). These <italic toggle="yes">cis-</italic>regulatory elements may aid in the discovery of candidate cancer biomarkers and enhance our knowledge of regulatory mechanisms in cancer. For example, <italic toggle="yes">CD70</italic> is reported as a tumor-specific biomarker in kidney cancer, which promotes immune escape by inducing cytotoxic effects on B and T lymphocytes. Using TSCRE, we found <italic toggle="yes">CD70</italic> was regulated by a distal enhancer (‘Pair_41_CRE330’) in kidney cancer, which were further validated by FANTOME5 enhancers and pan-cancer ATAC-seq links (Figure <xref rid="F3" ref-type="fig">3A</xref>). Notably, this enhancer exhibits a significant increase in H3K27ac signal in kidney cancer compared to nonmalignant samples (Figure <xref rid="F3" ref-type="fig">3B</xref>), which coincides with the upregulation of <italic toggle="yes">CD70</italic> (Figure <xref rid="F3" ref-type="fig">3C</xref>). Moreover, this enhancer demonstrated a high degree of cell type specificity, as it ranked first in chromatin accessibility (Figure <xref rid="F3" ref-type="fig">3D</xref>) and second in eRNA activity (Figure <xref rid="F3" ref-type="fig">3E</xref>) within kidney cancer. Especially, only a single CRE in colon cancer exhibits partial overlap with this enhancer (Figure <xref rid="F3" ref-type="fig">3A</xref>). These findings indicate this enhancer associated with <italic toggle="yes">CD70</italic> regulation is highly specific to kidney cancer. Another notable case is <italic toggle="yes">MERTK</italic> gene, which is known as an oncogene that promotes breast cancer progression (<xref rid="B12" ref-type="bibr">12</xref>). Consistently, nonmalignant samples encompass repressive CREs (known as silencers in SilencerDB) associated with <italic toggle="yes">MERTK</italic>. However, across all subtypes of breast cancer, there is a significant loss of H3K27me3 modification, coinciding with the upregulation of MERTK in most subtypes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3</xref>). These results suggest that dysregulated CREs in TSCRE are highly specific to tumorigenesis and underscore their potential role in elucidating the molecular mechanisms underlying pathogenesis.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>The detailed information of a distal CRE for <italic toggle="yes">CD70</italic>. <bold>(A)</bold> Visualization of ‘Pair_41_CRE330’ using UCSC Genome Browser. (B, C) A significant increase in H3K27ac signal <bold>(B)</bold> and mRNA expression <bold>(C)</bold> was observed in kidney cancer. (D, E) Kidney cancer exhibits the highest chromatin accessibility <bold>(D)</bold> and the second-highest level of eRNA activity <bold>(E)</bold> within this CRE.</p>
        </caption>
        <graphic xlink:href="zcad063fig3" position="float"/>
      </fig>
      <p>Similarly, dysregulated SCREs are also highly specific to tumorigenesis (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3B</xref>). For example, <italic toggle="yes">PDX1</italic>, a potential tumor marker in colorectal cancer (<xref rid="B55" ref-type="bibr">55</xref>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S4A</xref>), contains both a lost repressive SCRE (‘Pair_18_SCRE66’) and a gained active SCRE (‘Pair_10_SCRE127’, a super-enhancer cataloged in Reference (<xref rid="B34" ref-type="bibr">34</xref>)) in colorectal cancer. In nonmalignant tissues, <italic toggle="yes">PDX1</italic> is characterized by the presence of H3K27me3 signal and the absence of H3K27ac. In contrast, it undergoes a reduction in H3K27me3 and an increase in H3K27ac during tumorigenesis, accompanied by elevated mRNA expression. Additionally, this SCRE shows high cell type specificity, ranking first in both accessibility and eRNA activity.</p>
      <p>In addition, TSCRE serves as a valuable platform for identifying potential therapeutic targets associated with dysregulated elements. An exemplary case is the EGFR gene, which exhibits frequent overexpression in basal breast cancer and contributes to the aggressive behavior of this subtype (<xref rid="B56" ref-type="bibr">56</xref>). Recent investigations have explored EGFR inhibitors, such as gefitinib and erlotinib, as potential treatment modalities for basal breast cancer (<xref rid="B56" ref-type="bibr">56</xref>). Encouragingly, our findings demonstrate a significant association between the drug response to gefitinib and erlotinib and a gained active SCRE ("Pair_92_SCRE61’, a super-enhancer cataloged in Reference (<xref rid="B34" ref-type="bibr">34</xref>)) in EGFR specific to basal breast cancer (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S5</xref>). Remarkably, within TSCRE, a substantial proportion of CREs (628 993 out of 1 864 941) and SCREs (25 964 out of 68 253) are linked to drugs, suggesting their potential involvement in drug response or as therapeutic targets.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>TSCRE is a comprehensive open resource for providing dysregulated CREs and SCREs through the re-analysis of publicly available ChIP-seq data. In comparison to other existing databases, TSCRE possesses the following advantages: (i) To the best of our knowledge, TSCRE is the first comprehensive database focusing specifically on <italic toggle="yes">cis-</italic>regulatory elements in a highly cancer-associated context; (ii) TSCRE is the only database emphasizing the roles of both CREs and SCREs. (iii) In addition to super-enhancers, TSCRE also provides super repressive elements and other broad regions, which were modified with repressive marks (e.g. H3K27m3, H3K9me3) or other active marks (e.g. H3K4me3, H3K36me3). (iv) TSCRE provides detailed annotations for each CRE and SCRE, including gene annotation, mRNA expression, clinical prognosis, associated TFBSs, associated mutations and cancer-type specificity. These annotations assist biologists in identifying relevant biological features and discover novel cancer biomarkers. (v) TSCRE assesses the associations between dysregulated elements and drug response in cancer patients, potentially enabling more direct and impactful target therapy. (vi) TSCRE integrates the results of pathway and TF enrichment analysis to facilitate follow-up functional and mechanistic studies.</p>
    <p>In the future, TSCRE will be continuously updated as new histone modification profiling data become available in public databases. We also plan to incorporate other epigenetic marks, such as DNA methylation, and more drug response dataset into TSCRE. Additionally, we strongly encourage users to contribute to TSCRE by uploading their own data.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>zcad063_Supplemental_Files</label>
      <media xlink:href="zcad063_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>YYZ was supported by the National Natural Science Foundation of China (32200538), Shenzhen Science and Technology Innovation Commission (JCYJ20220530144815036, JCYJ20230807110309019), the Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University (ZSQYBRJH0025). XPS was supported by the National Natural Science Foundation of China (82170177/H0809), the Natural Science Foundation of Guangdong Province (2021A1515011334 and 2023A1515011976). XTL was supported by the National Natural Science Foundation of China (32200542).</p>
    <p><italic toggle="yes">Author contributions</italic>: <bold>Y.Y. Zheng:</bold> conceptualization, resources, supervision, funding acquisition, methodology, writing–original draft, writing–review and editing. <bold>J. Ren:</bold> resources, supervision, methodology, writing–review and editing. <bold>X.P. Shi:</bold> resources, supervision, funding acquisition, methodology, writing–review and editing. <bold>G.J. Peng:</bold> data curation, data analysis, writing–original draft, writing–review and editing. <bold>B.Y. Liu:</bold> data curation, data analysis, writing–original draft, writing–review and editing. <bold>M.H. Zheng:</bold> website construction, visualization, methodology, writing–review and editing. <bold>L.W.Y. Zhang:</bold> website construction, visualization, methodology, writing–review and editing. <bold>H.Q. Li:</bold> website construction, methodology. <bold>MN. Liu:</bold> data curation, writing–review and editing. <bold>Y. Liang:</bold> data curation, writing–review and editing. <bold>T.J. Chen:</bold> website construction, methodology. <bold>X.T. Luo:</bold> resources, methodology and funding acquisition.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>No new data were generated or analysed in support of this research.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcad063#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Cancer Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>The Young Scientists Fund of the National Natural Science Foundation of China [32200538, 32200542]; Shenzhen Science and Technology Innovation Commission [JCYJ20220530144815036, JCYJ20230807110309019]; The Natural Science Foundation of Guangdong Province [2021A1515011334, 2023A1515011976]; The National Natural Science Foundation of China [82170177/H0809]; Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University [ZSQYBRJH0025].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ong</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Corces</surname><given-names>V.G.</given-names></string-name></person-group><article-title>Enhancer function: new insights into the regulation of tissue-specific gene expression</article-title>. <source>Nat. Rev. Genet.</source><year>2011</year>; <volume>12</volume>:<fpage>283</fpage>–<lpage>293</lpage>.<pub-id pub-id-type="pmid">21358745</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pang</surname><given-names>B.</given-names></string-name>, <string-name><surname>van Weerd</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Hamoen</surname><given-names>F.L.</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>M.P.</given-names></string-name></person-group><article-title>Identification of non-coding silencer elements and their regulation of gene expression</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><year>2023</year>; <volume>24</volume>:<fpage>383</fpage>–<lpage>395</lpage>.<pub-id pub-id-type="pmid">36344659</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andersson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Sandelin</surname><given-names>A.</given-names></string-name></person-group><article-title>Determinants of enhancer and promoter activities of regulatory elements</article-title>. <source>Nat. Rev. Genet.</source><year>2020</year>; <volume>21</volume>:<fpage>71</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">31605096</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Madani Tonekaboni</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Haibe-Kains</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lupien</surname><given-names>M.</given-names></string-name></person-group><article-title>Large organized chromatin lysine domains help distinguish primitive from differentiated cell populations</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>499</fpage>.<pub-id pub-id-type="pmid">33479238</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whyte</surname><given-names>W.A.</given-names></string-name>, <string-name><surname>Orlando</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Hnisz</surname><given-names>D.</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Kagey</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Rahl</surname><given-names>P.B.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Master transcription factors and mediator establish super-enhancers at key cell identity genes</article-title>. <source>Cell</source>. <year>2013</year>; <volume>153</volume>:<fpage>307</fpage>–<lpage>319</lpage>.<pub-id pub-id-type="pmid">23582322</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Loh</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Tng</surname><given-names>J.Q.</given-names></string-name>, <string-name><surname>Lim</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Raju</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lieberman Aiden</surname><given-names>E.</given-names></string-name>, <string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Manikandan</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>H3K27me3-rich genomic regions can function as silencers to repress gene expression via chromatin interactions</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>719</fpage>.<pub-id pub-id-type="pmid">33514712</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hsieh</surname><given-names>I.Y.</given-names></string-name>, <string-name><surname>He</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>B.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>B.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>G.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis</article-title>. <source>Biomed. Pharmacother.</source><year>2020</year>; <volume>123</volume>:<fpage>109728</fpage>.<pub-id pub-id-type="pmid">31846842</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Loven</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hoke</surname><given-names>H.A.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Lau</surname><given-names>A.</given-names></string-name>, <string-name><surname>Orlando</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Vakoc</surname><given-names>C.R.</given-names></string-name>, <string-name><surname>Bradner</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title>. <source>Cell</source>. <year>2013</year>; <volume>153</volume>:<fpage>320</fpage>–<lpage>334</lpage>.<pub-id pub-id-type="pmid">23582323</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>X.</given-names></string-name>, <string-name><surname>Su</surname><given-names>J.</given-names></string-name>, <string-name><surname>Rodriguez</surname><given-names>B.</given-names></string-name>, <string-name><surname>Xi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes</article-title>. <source>Nat. Genet.</source><year>2015</year>; <volume>47</volume>:<fpage>1149</fpage>–<lpage>1157</lpage>.<pub-id pub-id-type="pmid">26301496</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Saiakhova</surname><given-names>A.</given-names></string-name>, <string-name><surname>Corradin</surname><given-names>O.</given-names></string-name>, <string-name><surname>Luppino</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Lovrenert</surname><given-names>K.</given-names></string-name>, <string-name><surname>Bartels</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Morrow</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Mack</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Dhillon</surname><given-names>G.</given-names></string-name>, <string-name><surname>Beard</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome</article-title>. <source>Nat. Commun.</source><year>2017</year>; <volume>8</volume>:<fpage>14400</fpage>.<pub-id pub-id-type="pmid">28169291</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Maryam</surname><given-names>A.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ramakrishnan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>V.W.S.</given-names></string-name>, <string-name><surname>Cheuk</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>2242</fpage>.<pub-id pub-id-type="pmid">33854062</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Meng</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Yi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Broad genic repression domains signify enhanced silencing of oncogenes</article-title>. <source>Nat. Commun.</source><year>2020</year>; <volume>11</volume>:<fpage>5560</fpage>.<pub-id pub-id-type="pmid">33144558</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bouras</surname><given-names>E.</given-names></string-name>, <string-name><surname>Karakioulaki</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bougioukas</surname><given-names>K.I.</given-names></string-name>, <string-name><surname>Aivaliotis</surname><given-names>M.</given-names></string-name>, <string-name><surname>Tzimagiorgis</surname><given-names>G.</given-names></string-name>, <string-name><surname>Chourdakis</surname><given-names>M.</given-names></string-name></person-group><article-title>Gene promoter methylation and cancer: an umbrella review</article-title>. <source>Gene</source>. <year>2019</year>; <volume>710</volume>:<fpage>333</fpage>–<lpage>340</lpage>.<pub-id pub-id-type="pmid">31202904</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qamra</surname><given-names>A.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>M.</given-names></string-name>, <string-name><surname>Padmanabhan</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>J.J.T.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Leong</surname><given-names>Y.S.</given-names></string-name>, <string-name><surname>Lee Lim</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Ooi</surname><given-names>W.F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma</article-title>. <source>Cancer Discov.</source><year>2017</year>; <volume>7</volume>:<fpage>630</fpage>–<lpage>651</lpage>.<pub-id pub-id-type="pmid">28320776</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mack</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Pajtler</surname><given-names>K.W.</given-names></string-name>, <string-name><surname>Chavez</surname><given-names>L.</given-names></string-name>, <string-name><surname>Okonechnikov</surname><given-names>K.</given-names></string-name>, <string-name><surname>Bertrand</surname><given-names>K.C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Erkek</surname><given-names>S.</given-names></string-name>, <string-name><surname>Federation</surname><given-names>A.</given-names></string-name>, <string-name><surname>Song</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling</article-title>. <source>Nature</source>. <year>2018</year>; <volume>553</volume>:<fpage>101</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">29258295</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>G.H.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Qi</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Teng</surname><given-names>X.Q.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H.H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>J.</given-names></string-name></person-group><article-title>Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance</article-title>. <source>J. Exp. Clin. Cancer Res.</source><year>2021</year>; <volume>40</volume>:<fpage>174</fpage>.<pub-id pub-id-type="pmid">34011395</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name></person-group><article-title>Super-enhancer function and its application in cancer targeted therapy</article-title>. <source>NPJ Precis. Oncol.</source><year>2020</year>; <volume>4</volume>:<fpage>2</fpage>.<pub-id pub-id-type="pmid">32128448</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hou</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>W.</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>F.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name></person-group><article-title>Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma</article-title>. <source>J. Transl. Med.</source><year>2011</year>; <volume>9</volume>:<fpage>39</fpage>.<pub-id pub-id-type="pmid">21481255</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tseng</surname><given-names>A.W.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Breslin</surname><given-names>M.B.</given-names></string-name>, <string-name><surname>Lan</surname><given-names>M.S.</given-names></string-name></person-group><article-title>Tumor-specific promoter-driven adenoviral therapy for insulinoma</article-title>. <source>Cell Oncol (Dordr)</source>. <year>2016</year>; <volume>39</volume>:<fpage>279</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">26902080</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muratani</surname><given-names>M.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>N.</given-names></string-name>, <string-name><surname>Ooi</surname><given-names>W.F.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Qamra</surname><given-names>A.</given-names></string-name>, <string-name><surname>Tay</surname><given-names>S.T.</given-names></string-name>, <string-name><surname>Malik</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements</article-title>. <source>Nat. Commun.</source><year>2014</year>; <volume>5</volume>:<fpage>4361</fpage>.<pub-id pub-id-type="pmid">25008978</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heintzman</surname><given-names>N.D.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Hon</surname><given-names>G.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ching</surname><given-names>C.W.</given-names></string-name>, <string-name><surname>Hawkins</surname><given-names>R.D.</given-names></string-name>, <string-name><surname>Barrera</surname><given-names>L.O.</given-names></string-name>, <string-name><surname>Van Calcar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ching</surname><given-names>K.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome</article-title>. <source>Nat. Genet.</source><year>2007</year>; <volume>39</volume>:<fpage>311</fpage>–<lpage>318</lpage>.<pub-id pub-id-type="pmid">17277777</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akhtar-Zaidi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Cowper-Sal-lari</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corradin</surname><given-names>O.</given-names></string-name>, <string-name><surname>Saiakhova</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bartels</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Balasubramanian</surname><given-names>D.</given-names></string-name>, <string-name><surname>Myeroff</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lutterbaugh</surname><given-names>J.</given-names></string-name>, <string-name><surname>Jarrar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kalady</surname><given-names>M.F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Epigenomic enhancer profiling defines a signature of colon cancer</article-title>. <source>Science</source>. <year>2012</year>; <volume>336</volume>:<fpage>736</fpage>–<lpage>739</lpage>.<pub-id pub-id-type="pmid">22499810</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hitz</surname><given-names>B.C.</given-names></string-name>, <string-name><surname>Gabdank</surname><given-names>I.</given-names></string-name>, <string-name><surname>Hilton</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Kagda</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>B.</given-names></string-name>, <string-name><surname>Myers</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Sud</surname><given-names>P.</given-names></string-name>, <string-name><surname>Jou</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>New developments on the Encyclopedia of DNA Elements (ENCODE) data portal</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D882</fpage>–<lpage>D889</lpage>.<pub-id pub-id-type="pmid">31713622</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mei</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D729</fpage>–<lpage>D735</lpage>.<pub-id pub-id-type="pmid">30462313</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zou</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Ohta</surname><given-names>T.</given-names></string-name>, <string-name><surname>Miura</surname><given-names>F.</given-names></string-name>, <string-name><surname>Oki</surname><given-names>S.</given-names></string-name></person-group><article-title>ChIP-Atlas 2021 update: a data-mining suite for exploring epigenomic landscapes by fully integrating ChIP-seq, ATAC-seq and bisulfite-seq data</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>W175</fpage>–<lpage>W182</lpage>.<pub-id pub-id-type="pmid">35325188</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Song</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>SEdb 2.0: a comprehensive super-enhancer database of human and mouse</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D280</fpage>–<lpage>D290</lpage>.<pub-id pub-id-type="pmid">36318264</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name></person-group><article-title>SEA version 3.0: a comprehensive extension and update of the Super-Enhancer archive</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D198</fpage>–<lpage>D203</lpage>.<pub-id pub-id-type="pmid">31667506</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name></person-group><article-title>dbSUPER: a database of super-enhancers in mouse and human genome</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D164</fpage>–<lpage>D171</lpage>.<pub-id pub-id-type="pmid">26438538</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corces</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Granja</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Shams</surname><given-names>S.</given-names></string-name>, <string-name><surname>Louie</surname><given-names>B.H.</given-names></string-name>, <string-name><surname>Seoane</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>W.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Groeneveld</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>C.K.</given-names></string-name>, <string-name><surname>Cho</surname><given-names>S.W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The chromatin accessibility landscape of primary human cancers</article-title>. <source>Science</source>. <year>2018</year>; <volume>362</volume>:<fpage>eaav1898</fpage>.<pub-id pub-id-type="pmid">30361341</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Song</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kuang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>D.</given-names></string-name>, <string-name><surname>Choudhary</surname><given-names>M.N.K.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The 3D genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions</article-title>. <source>Genome Biol.</source><year>2018</year>; <volume>19</volume>:<fpage>151</fpage>.<pub-id pub-id-type="pmid">30286773</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noguchi</surname><given-names>S.</given-names></string-name>, <string-name><surname>Arakawa</surname><given-names>T.</given-names></string-name>, <string-name><surname>Fukuda</surname><given-names>S.</given-names></string-name>, <string-name><surname>Furuno</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hasegawa</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hori</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ishikawa-Kato</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kaida</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kaiho</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kanamori-Katayama</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>FANTOM5 CAGE profiles of human and mouse samples</article-title>. <source>Sci. Data</source>. <year>2017</year>; <volume>4</volume>:<fpage>170112</fpage>.<pub-id pub-id-type="pmid">28850106</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fishilevich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Nudel</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rappaport</surname><given-names>N.</given-names></string-name>, <string-name><surname>Hadar</surname><given-names>R.</given-names></string-name>, <string-name><surname>Plaschkes</surname><given-names>I.</given-names></string-name>, <string-name><surname>Iny Stein</surname><given-names>T.</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kohn</surname><given-names>A.</given-names></string-name>, <string-name><surname>Twik</surname><given-names>M.</given-names></string-name>, <string-name><surname>Safran</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>GeneHancer: genome-wide integration of enhancers and target genes in GeneCards</article-title>. <source>Database (Oxford)</source>. <year>2017</year>; <volume>2017</volume>:<fpage>bax028</fpage>.<pub-id pub-id-type="pmid">28605766</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeng</surname><given-names>W.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>X.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>R.</given-names></string-name></person-group><article-title>SilencerDB: a comprehensive database of silencers</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D221</fpage>–<lpage>D228</lpage>.<pub-id pub-id-type="pmid">33045745</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hnisz</surname><given-names>D.</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Lau</surname><given-names>A.</given-names></string-name>, <string-name><surname>Saint-Andre</surname><given-names>V.</given-names></string-name>, <string-name><surname>Sigova</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Hoke</surname><given-names>H.A.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Super-enhancers in the control of cell identity and disease</article-title>. <source>Cell</source>. <year>2013</year>; <volume>155</volume>:<fpage>934</fpage>–<lpage>947</lpage>.<pub-id pub-id-type="pmid">24119843</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>F.W.</given-names></string-name>, <string-name><surname>Jane-Valbuena</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kryukov</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>E.R.</given-names></string-name>, <string-name><surname>Barretina</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gelfand</surname><given-names>E.T.</given-names></string-name>, <string-name><surname>Bielski</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Next-generation characterization of the Cancer Cell Line Encyclopedia</article-title>. <source>Nature</source>. <year>2019</year>; <volume>569</volume>:<fpage>503</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research, N.</collab><string-name><surname>Weinstein</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Collisson</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Mills</surname><given-names>G.B.</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>K.R.</given-names></string-name>, <string-name><surname>Ozenberger</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Ellrott</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shmulevich</surname><given-names>I.</given-names></string-name>, <string-name><surname>Sander</surname><given-names>C.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>J.M</given-names></string-name></person-group><article-title>The cancer genome atlas pan-cancer analysis project</article-title>. <source>Nat. Genet.</source><year>2013</year>; <volume>45</volume>:<fpage>1113</fpage>–<lpage>1120</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>H.</given-names></string-name></person-group><article-title>A high-resolution map of Human enhancer RNA loci characterizes super-enhancer activities in cancer</article-title>. <source>Cancer Cell</source>. <year>2020</year>; <volume>38</volume>:<fpage>701</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">33007258</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tate</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Bamford</surname><given-names>S.</given-names></string-name>, <string-name><surname>Jubb</surname><given-names>H.C.</given-names></string-name>, <string-name><surname>Sondka</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Beare</surname><given-names>D.M.</given-names></string-name>, <string-name><surname>Bindal</surname><given-names>N.</given-names></string-name>, <string-name><surname>Boutselakis</surname><given-names>H.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Creatore</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dawson</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>COSMIC: the catalogue of somatic mutations In cancer</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D941</fpage>–<lpage>D947</lpage>.<pub-id pub-id-type="pmid">30371878</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Song</surname><given-names>C.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ning</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>KnockTF: a comprehensive human gene expression profile database with knockdown/knockout of transcription factors</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D93</fpage>–<lpage>D100</lpage>.<pub-id pub-id-type="pmid">31598675</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rees</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Seashore-Ludlow</surname><given-names>B.</given-names></string-name>, <string-name><surname>Cheah</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Price</surname><given-names>E.V.</given-names></string-name>, <string-name><surname>Gill</surname><given-names>S.</given-names></string-name>, <string-name><surname>Javaid</surname><given-names>S.</given-names></string-name>, <string-name><surname>Coletti</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>V.L.</given-names></string-name>, <string-name><surname>Bodycombe</surname><given-names>N.E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</article-title>. <source>Nat. Chem. Biol.</source><year>2016</year>; <volume>12</volume>:<fpage>109</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">26656090</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Soares</surname><given-names>J.</given-names></string-name>, <string-name><surname>Greninger</surname><given-names>P.</given-names></string-name>, <string-name><surname>Edelman</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Lightfoot</surname><given-names>H.</given-names></string-name>, <string-name><surname>Forbes</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bindal</surname><given-names>N.</given-names></string-name>, <string-name><surname>Beare</surname><given-names>D.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>I.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D955</fpage>–<lpage>D961</lpage>.<pub-id pub-id-type="pmid">23180760</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name></person-group><article-title>Fast and accurate long-read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>. <year>2010</year>; <volume>26</volume>:<fpage>589</fpage>–<lpage>595</lpage>.<pub-id pub-id-type="pmid">20080505</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Handsaker</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wysoker</surname><given-names>A.</given-names></string-name>, <string-name><surname>Fennell</surname><given-names>T.</given-names></string-name>, <string-name><surname>Ruan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Homer</surname><given-names>N.</given-names></string-name>, <string-name><surname>Marth</surname><given-names>G.</given-names></string-name>, <string-name><surname>Abecasis</surname><given-names>G.</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name><collab>Genome Project Data Processing, S</collab></person-group><article-title>The sequence alignment/map format and SAMtools</article-title>. <source>Bioinformatics</source>. <year>2009</year>; <volume>25</volume>:<fpage>2078</fpage>–<lpage>2079</lpage>.<pub-id pub-id-type="pmid">19505943</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quinlan</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>I.M.</given-names></string-name></person-group><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title>. <source>Bioinformatics</source>. <year>2010</year>; <volume>26</volume>:<fpage>841</fpage>–<lpage>842</lpage>.<pub-id pub-id-type="pmid">20110278</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>T.</given-names></string-name></person-group><article-title>Use model-based analysis of ChIP-Seq (MACS) to analyze short reads generated by sequencing protein-DNA interactions in embryonic stem cells</article-title>. <source>Methods Mol. Biol.</source><year>2014</year>; <volume>1150</volume>:<fpage>81</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">24743991</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>D.</given-names></string-name>, <string-name><surname>Langmead</surname><given-names>B.</given-names></string-name>, <string-name><surname>Salzberg</surname><given-names>S.L.</given-names></string-name></person-group><article-title>HISAT: a fast spliced aligner with low memory requirements</article-title>. <source>Nat. Methods</source>. <year>2015</year>; <volume>12</volume>:<fpage>357</fpage>–<lpage>360</lpage>.<pub-id pub-id-type="pmid">25751142</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anders</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pyl</surname><given-names>P.T.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name></person-group><article-title>HTSeq–a Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source>. <year>2015</year>; <volume>31</volume>:<fpage>166</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">25260700</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name>, <string-name><surname>Anders</surname><given-names>S.</given-names></string-name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ross-Innes</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Stark</surname><given-names>R.</given-names></string-name>, <string-name><surname>Teschendorff</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Ali</surname><given-names>H.R.</given-names></string-name>, <string-name><surname>Dunning</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>G.D.</given-names></string-name>, <string-name><surname>Gojis</surname><given-names>O.</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>I.O.</given-names></string-name>, <string-name><surname>Green</surname><given-names>A.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Differential oestrogen receptor binding is associated with clinical outcome in breast cancer</article-title>. <source>Nature</source>. <year>2012</year>; <volume>481</volume>:<fpage>389</fpage>–<lpage>393</lpage>.<pub-id pub-id-type="pmid">22217937</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heinz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Benner</surname><given-names>C.</given-names></string-name>, <string-name><surname>Spann</surname><given-names>N.</given-names></string-name>, <string-name><surname>Bertolino</surname><given-names>E.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y.C.</given-names></string-name>, <string-name><surname>Laslo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>J.X.</given-names></string-name>, <string-name><surname>Murre</surname><given-names>C.</given-names></string-name>, <string-name><surname>Singh</surname><given-names>H.</given-names></string-name>, <string-name><surname>Glass</surname><given-names>C.K.</given-names></string-name></person-group><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title>. <source>Mol. Cell</source>. <year>2010</year>; <volume>38</volume>:<fpage>576</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">20513432</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maeser</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gruener</surname><given-names>R.F.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>R.S.</given-names></string-name></person-group><article-title>oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data</article-title>. <source>Brief Bioinform.</source><year>2021</year>; <volume>22</volume>:<fpage>bbab260</fpage>.<pub-id pub-id-type="pmid">34260682</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheffield</surname><given-names>N.C.</given-names></string-name>, <string-name><surname>Bock</surname><given-names>C.</given-names></string-name></person-group><article-title>LOLA: enrichment analysis for genomic region sets and regulatory elements in R and bioconductor</article-title>. <source>Bioinformatics</source>. <year>2016</year>; <volume>32</volume>:<fpage>587</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">26508757</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>X.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.S.</given-names></string-name></person-group><article-title>Cistrome-GO: a web server for functional enrichment analysis of transcription factor ChIP-seq peaks</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>W206</fpage>–<lpage>W211</lpage>.<pub-id pub-id-type="pmid">31053864</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>W.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>J.</given-names></string-name></person-group><article-title>The role of hepatocyte nuclear factor 4alpha (HNF4alpha) in tumorigenesis</article-title>. <source>Front. Oncol.</source><year>2022</year>; <volume>12</volume>:<fpage>1011230</fpage>.<pub-id pub-id-type="pmid">36249028</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ballian</surname><given-names>N.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Brunicardi</surname><given-names>F.C.</given-names></string-name></person-group><article-title>Transcription factor PDX-1 in human colorectal adenocarcinoma: a potential tumor marker?</article-title>. <source>World J. Gastroenterol.</source><year>2008</year>; <volume>14</volume>:<fpage>5823</fpage>–<lpage>5826</lpage>.<pub-id pub-id-type="pmid">18855980</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Masuda</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bartholomeusz</surname><given-names>C.</given-names></string-name>, <string-name><surname>Doihara</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hortobagyi</surname><given-names>G.N.</given-names></string-name>, <string-name><surname>Ueno</surname><given-names>N.T.</given-names></string-name></person-group><article-title>Role of epidermal growth factor receptor in breast cancer</article-title>. <source>Breast Cancer Res. Treat.</source><year>2012</year>; <volume>136</volume>:<fpage>331</fpage>–<lpage>345</lpage>.<pub-id pub-id-type="pmid">23073759</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id>
    <journal-id journal-id-type="publisher-id">narcancer</journal-id>
    <journal-title-group>
      <journal-title>NAR Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2632-8674</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10782923</article-id>
    <article-id pub-id-type="doi">10.1093/narcan/zcad063</article-id>
    <article-id pub-id-type="publisher-id">zcad063</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00030</subject>
        <subject>AcademicSubjects/SCI00980</subject>
        <subject>AcademicSubjects/SCI01060</subject>
        <subject>AcademicSubjects/SCI01140</subject>
        <subject>AcademicSubjects/SCI01180</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Cancer Data Resource</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>TSCRE: a comprehensive database for tumor-specific <italic toggle="yes">cis</italic>-regulatory elements</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Peng</surname>
          <given-names>Guanjie</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Bingyuan</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zheng</surname>
          <given-names>Mohan</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Luowanyue</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Huiqin</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Mengni</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liang</surname>
          <given-names>Yuan</given-names>
        </name>
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Tianjian</given-names>
        </name>
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Luo</surname>
          <given-names>Xiaotong</given-names>
        </name>
        <aff><institution>Guangdong Institute of Gastroenterology, Department of General Surgery</institution>, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5774-8568</contrib-id>
        <name>
          <surname>Shi</surname>
          <given-names>Xianping</given-names>
        </name>
        <!--xianping.shi@gzhmu.edu.cn-->
        <aff><institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Affiliated Cancer Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University</institution>, Guangzhou <addr-line>510120</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4161-1292</contrib-id>
        <name>
          <surname>Ren</surname>
          <given-names>Jian</given-names>
        </name>
        <!--renjian@sysucc.org.cn-->
        <aff><institution>State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University</institution>, Guangzhou <addr-line>510060</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5692-8903</contrib-id>
        <name>
          <surname>Zheng</surname>
          <given-names>Yueyuan</given-names>
        </name>
        <!--zhengyy86@mail.sysu.edu.cn-->
        <aff><institution>Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, Shenzhen <addr-line>518107</addr-line>, <country country="TW">P.R. China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 13509645425; Email: <email>zhengyy86@mail.sysu.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Jian Ren. Tel: +86 13751761881; Email: <email>renjian@sysucc.org.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Xianping Shi. Tel: +86 13570066303; Email: <email>xianping.shi@gzhmu.edu.cn</email></corresp>
      <fn id="FN1">
        <p>The first four authors should be regarded as joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-01-11">
      <day>11</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>11</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <volume>6</volume>
    <issue>1</issue>
    <elocation-id>zcad063</elocation-id>
    <history>
      <date date-type="accepted">
        <day>31</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>18</day>
        <month>11</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>28</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of NAR Cancer.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="zcad063.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p><italic toggle="yes">Cis</italic>-regulatory elements (CREs) and super <italic toggle="yes">cis-</italic>regulatory elements (SCREs) are non-coding DNA regions which influence the transcription of nearby genes and play critical roles in development. Dysregulated CRE and SCRE activities have been reported to alter the expression of oncogenes and tumor suppressors, thereby regulating cancer hallmarks. To address the strong need for a comprehensive catalogue of dysregulated CREs and SCREs in human cancers, we present TSCRE (<ext-link xlink:href="http://tscre.zsqylab.com/" ext-link-type="uri">http://tscre.zsqylab.com/</ext-link>), an open resource providing tumor-specific and cell type-specific CREs and SCREs derived from the re-analysis of publicly available histone modification profiles. Currently, TSCRE contains 1 864 941 dysregulated CREs and 68 253 dysregulated SCREs identified from 1366 human patient samples spanning 17 different cancer types and 9 histone marks. Over 95% of these elements have been validated in public resources. TSCRE offers comprehensive annotations for each element, including associated genes, expression patterns, clinical prognosis, somatic mutations, transcript factor binding sites, cancer-type specificity, and drug response. Additionally, TSCRE integrates pathway and transcript factor enrichment analyses for each study, enabling in-depth functional and mechanistic investigations. Furthermore, TSCRE provides an interactive interface for users to explore any CRE and SCRE of interest. We believe TSCRE will be a highly valuable platform for the community to discover candidate cancer biomarkers.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="zcad063figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32200538</award-id>
        <award-id>32200542</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Shenzhen Science and Technology Innovation Commission</institution>
            <institution-id institution-id-type="DOI">10.13039/501100010877</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>JCYJ20220530144815036</award-id>
        <award-id>JCYJ20230807110309019</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Guangdong Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003453</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2021A1515011334</award-id>
        <award-id>2023A1515011976</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>82170177/H0809</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Sun Yat-sen University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100002402</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>ZSQYBRJH0025</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p><italic toggle="yes">Cis</italic>-regulatory elements (CREs), including enhancers, promoters, and silencers, are crucial for controlling gene expression during development (<xref rid="B1" ref-type="bibr">1–3</xref>). Super <italic toggle="yes">cis-</italic>regulatory elements (SCREs), characterized by large clusters of regulatory regions, are essential in determining cell differentiation and identity (<xref rid="B4" ref-type="bibr">4–6</xref>). Numerous CREs and SCREs have been identified across human tissues and diseases. In the context of human cancers, the aberrant activity of CREs and SCREs can lead to the dysregulation of oncogenes and tumor suppressors, disrupting normal cellular processes and promoting cancer hallmarks such as proliferation, invasion and metastasis (<xref rid="B7" ref-type="bibr">7–9</xref>). Dysregulations in enhancers, super-enhancers, silencers, and promoters are common epigenetic alterations. For example, aberrant regulation of enhancers and super-enhancers have been frequently observed in various cancers, resulting in the upregulation of key oncogenes, such as <italic toggle="yes">MYC</italic> and <italic toggle="yes">FOXQ1</italic> in colorectal cancer (<xref rid="B10" ref-type="bibr">10</xref>), as well as <italic toggle="yes">FOXC1</italic> and <italic toggle="yes">MET</italic> in triple-negative breast cancer (<xref rid="B11" ref-type="bibr">11</xref>). Additionally, many silencers, characterized by extensive broad H3K27me3 modification, exhibit a significant reduction in H3K27me3 modification size in human tumors, thereby promoting the activation of oncogenes such as <italic toggle="yes">MYH11</italic> and <italic toggle="yes">EGFR</italic> (<xref rid="B12" ref-type="bibr">12</xref>). Moreover, dysregulation of promoters, including promoter hypermethylation and alterations in H3K4me3 along with H3K27ac, is frequently observed in cancer (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>). These dysregulations of CREs and SCREs exhibit specificity towards particular cancer types or subtypes, reflecting the unique epigenomic landscapes of different cells and tumors (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>). Recent studies have highlighted the potential of dysregulated CREs and SCREs as promising targets for cancer diagnosis and treatment (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). For instance, the exclusive activity of the <italic toggle="yes">INSM1</italic> promoter in insulinoma tumors has been leveraged for adenoviral therapy in insulinoma treatment (<xref rid="B19" ref-type="bibr">19</xref>). Therefore, the accumulating evidence for the essential roles of dysregulated CREs and SCREs in cancer biology, emphasizes the urgent need to comprehensively catalog dysregulated CREs and SCREs across various human cancer types.</p>
    <p>Previous studies have demonstrated the efficiency and robustness of histone modification profiling in identifying distinct classes of regulatory elements (<xref rid="B20" ref-type="bibr">20–22</xref>). For example, promoters can be identified by the histone mark H3K4me3, enhancers by H3K4me1, active regulatory elements by H3K27ac, and repressive elements by either H3K27me3 or H3K9me3 (<xref rid="B18" ref-type="bibr">18</xref>). With the rapid accumulation of chromatin immunoprecipitation sequencing (ChIP-seq) data on histone marks, several CRE and SCRE databases have been developed, such as ENCODE (<xref rid="B23" ref-type="bibr">23</xref>), CistromeDB (<xref rid="B24" ref-type="bibr">24</xref>), ChIP-Atlas (<xref rid="B25" ref-type="bibr">25</xref>), SEdb v2.0 (<xref rid="B26" ref-type="bibr">26</xref>), SEA v3.0 (<xref rid="B27" ref-type="bibr">27</xref>) and dbSUPER (<xref rid="B28" ref-type="bibr">28</xref>). These databases serve as valuable resources for investigating <italic toggle="yes">cis-</italic>regulatory elements, but they primarily focus on profiling of CREs or SCREs within individual tissues and cells. There is an urgent need for the collection of feature-specific dysregulated elements in human cancers (e.g. tumor-specific, metastasis-specific, and subtype-specific elements). Additionally, besides super-enhancers, other broad regulatory elements, such as super repressive elements and broad H3K4me3 regions, have also been implicated in cancer (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>), emphasizing the importance of their efficient identification and characterization. Moreover, further research on dysregulated CREs and SCREs heavily relies on reliable regulatory annotation, including genetic and epigenetic annotation, as well as association analyses involving transcription factors, cancer pathways, clinical prognosis, and response to anticancer drugs. Therefore, it is necessary to develop a comprehensive database dedicated to cancer-associated CREs and SCREs, elucidating their regulatory mechanisms in a highly cancer-specific context.</p>
    <p>Here, we present TSCRE (<ext-link xlink:href="http://tscre.zsqylab.com/" ext-link-type="uri">http://tscre.zsqylab.com/</ext-link>), a comprehensive open resource of tumor-specific and cell type-specific CREs and SCREs derived through extensive re-analyses of public histone modification profiling data in human cancers (Figure <xref rid="F1" ref-type="fig">1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). Using TSCRE, users are able to efficiently and intuitively explore dysregulated CREs or SCREs of interest in various cancer types of contrast experiments, such as ‘tumor vs. nonmalignant’, ‘metastasis vs. primary’, "mutant vs. wildtype’. We believe this platform will greatly benefit the research community by aiding in the screening of candidate CREs and SCREs, as well as facilitating the identification of relevant transcriptional regulators in human cancers.</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Overall design and construction of TSCRE.</p>
      </caption>
      <graphic xlink:href="zcad063fig1" position="float"/>
    </fig>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection</title>
      <p>A systematic search was conducted to find out cancer-associated histone modification profiles. Firstly, the GEO and SRA database were searched using keywords relating to nine of better-known histone markers (including H3K27ac, H3K4me3, H3K4me2, H3K4me1, H3K36me3, H3K9ac, H3K79me2, H3K9me3 and H3K27me3), along with the term ‘Genome binding/occupancy profiling by high throughput sequencing’. Datasets were restricted to human studies published before February 2023. Then we performed a manual screening and reserved studies that met the following criteria: 1) inclusion of tumor tissue or cancer cell lines, 2) samples in each study that could be compared based on a specific biological condition, including ‘tumor vs. non-malignant,’ ‘metastasis vs. primary,’ ‘mutant vs. wild-type’ or ‘subtype1 vs. subtype2’ and 3) presence of at least two biological replicates for each condition. In addition, matched RNA-seq data from the corresponding studies were downloaded when available.</p>
      <p>The following additional datasets were collected: long-range interactions between genes and distal regulatory regions, including pan-cancer ‘enhancer-to-gene’ links from TCGA ATAC-seq projects (<xref rid="B29" ref-type="bibr">29</xref>), Hi-C loops from 3D Genome Browser (<xref rid="B30" ref-type="bibr">30</xref>), and HiChIP loops from matched studies. Other <italic toggle="yes">cis-</italic>regulatory elements were obtained from public resources, containing DNase I-hypersensitive sites (DHSs) from the ENCODE project (<xref rid="B23" ref-type="bibr">23</xref>), CREs from the FANTOM5 project (<xref rid="B31" ref-type="bibr">31</xref>), enhancers from GeneHancer (<xref rid="B32" ref-type="bibr">32</xref>), silencers from SilencerDB (<xref rid="B33" ref-type="bibr">33</xref>) and super-enhancers from a recent publication (<xref rid="B34" ref-type="bibr">34</xref>). Multi-omics data of pan-cancer tissues and cell lines were extracted from TCGA and DepMap projects, containing mRNA expression, somatic mutations, chromatin accessibility, clinical data and CRISPR scores (<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>). In addition, we also obtained enhancer RNA (eRNA) expression from the TCeA Portal and mutations from COSMIC (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>). TFBSs from the ENCODE project and TF target genes from KnockTF were also included in our database (<xref rid="B39" ref-type="bibr">39</xref>). Lastly, we acquired pharmacogenomic data from GDSC2 and CTRP2, which involved drug response data from 198 and 545 compounds in various cancer lineages (<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Data preprocessing</title>
      <p>Raw ChIP-seq reads were trimmed using Trim-galore (version 0.6.6) and then aligned to the GRCh38 genome (ENSEMBL release 84) using BWA (version 0.7.17) with default parameters (<xref rid="B42" ref-type="bibr">42</xref>). Then uniquely mapped reads were extracted and sorted using SAMtools (version 1.7) program with the ‘-q 1’ option (<xref rid="B43" ref-type="bibr">43</xref>). PCR duplicates were removed using the Picard MarkDuplicates tool (version 2.26.2), and ENCODE blacklist regions were excluded using BEDtools (version v2.26.0) (<xref rid="B44" ref-type="bibr">44</xref>). MACS2 (Model-Based Analysis of ChIP-Seq, version 2.2.6) was applied to call peaks (refer to CREs) with the options ‘-q 0.01 –extsize = 146 –nomodel’ (<xref rid="B45" ref-type="bibr">45</xref>). Samples meeting all the following criteria are retained for further analysis: (i) duplication rates &lt;0.5; (ii) mapping rates &gt;0.6; (iii) at least 5 million usable fragments for narrow marks and 15 million for broad marks; (iv) peaks &gt;500 and fraction of reads in peaks (FRiP) ≥1%.</p>
      <p>Similarly, raw RNA-seq reads were processed to remove low-quality reads using Trim-galore (version 0.6.6) with default parameters. High-quality reads were then aligned to the GRCh38 genome using HISAT2 (version 7.2.0) and gene quantification was performed using the htseq-count program (version 0.11.3) with default settings (<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). Samples with a mapping rate &gt;0.6 and at least 10 million usable fragments were selected for differential gene expression analysis. The DESeq2 package or Wilcoxon test (≥8 samples in each given condition) were applied to identify differentially expressed genes, employing the criteria of ‘adjusted <italic toggle="yes">P</italic>-value &lt;0.05 and absolute fold-change &gt;1.5’ (<xref rid="B48" ref-type="bibr">48</xref>).</p>
    </sec>
    <sec id="SEC2-3">
      <title>Dysregulated CRE/SCRE identification</title>
      <p>Peaks modified by different histone markers, as identified in the previous section, were considered as CREs. DiffBind (version 3.6.5) was then used to compare CREs between two conditions and those with a fold change ≥1.5 and FDR &lt;0.05 were selected as dysregulated CREs (<xref rid="B49" ref-type="bibr">49</xref>).</p>
      <p>Among SCREs, the most extensively studied subset are super-enhancers, usually marked by H3K27ac modification. Rank Order of Super Enhancers (ROSE) is a commonly used method for identifying super-enhancers (<xref rid="B5" ref-type="bibr">5</xref>). Briefly, ROSE merged enhancer elements within a 12.5-kb distance and arranges them in decreasing order of intensities. Super-enhancers are then defined as stitching elements exhibiting a tangent slope with an inflection point value ≥1. ROSE (version 1.0) was also applied to identify super repressive elements enriched with H3K27me3 modification (<xref rid="B6" ref-type="bibr">6</xref>). Considering the potential variations in the stitching distance for different histone marks, we initially determined the most suitable distance for each histone mark by analyzing the histone modification peaks across various cell types from the ENCODE project. We merged peaks within different stitching distances for each dataset, ranging from 0.5 to 24 kb with 0.5 kb increments, and identified SCREs at each distance. We then counted the total number of peaks contained in SCREs and selected the optimal distance when the increasing number at that distance stabilized compared to the previous distance. As shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>, H3K27ac and H3K27me3 peaks within SCREs reached stability at 12 and 5 kb, respectively, which were close to the reported values of 12.5 and 4 kb. After obtaining the optimal distance for each histone marker (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>), we used ROSE to identify SCREs for each sample. Next, we employed the BEDtools multiinter function to find a consensus SCRE set of unique genomic intervals presenting in at least two samples for each study. Finally, DiffBind program was applied to identify the dysregulated SCREs and those with a fold change ≥1.5 and <italic toggle="yes">P</italic> value &lt;0.05 were selected.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Annotations of dysregulated CRE/SCREs</title>
      <p>We validated the accuracy of CREs and SCREs by checking whether they overlapped with regulatory regions obtained from ENCODE, FANTOM5, GeneHancer, SilencerDB and other existing literature (<xref rid="B34" ref-type="bibr">34</xref>). We then applied three gene annotation strategies to find the associated genes for each element. First, we mapped CREs to the nearest genes using the Homer annotatePeaks.pl function (<xref rid="B50" ref-type="bibr">50</xref>), while mapping SCREs to the nearest or overlapping genes with the help of ROSE_geneMapper.py function. Second, we associated distal CREs and SCREs with ATAC-seq-linked genes, which were established by the TCGA consortium based on the correlation between ATAC-Seq peaks and the expression levels of neighboring genes. Lastly, we assigned distal CREs and SCREs to their respective genes using Hi-C and HiChIP loops. To assist researchers in identifying the most relevant regulatory genes, we calculated mRNA expression level for each associated gene from available matched samples, pan-cancer tissues as well as cancer cell lines, and examine the survival outcome in cancer samples. Furthermore, associated TFBSs and somatic mutations were assigned to each CRE and SCRE using the BEDTools intersect program.</p>
    </sec>
    <sec id="SEC2-5">
      <title>Assessing cancer-type specificity and examining associations with drug response</title>
      <p>The cancer-type specificity of each regulatory element was determined by calculating its overlap with other elements in TSCRE, as well as by assessing the chromatin accessibility and enhancer RNA activity in the TCGA pan-cancer landscape. Additionally, we employed calcPhenotype function from the oncoPredict package to impute the drug response from GDSC and CTRP cancer cell lines to TCGA patient samples, after which we calculated the associations of each regulatory element with the imputed drug response (<xref rid="B51" ref-type="bibr">51</xref>). To achieve this, we trained linear ridge regression models using the expression levels and drug sensitivity scores of the cancer cell lines from GDSC and CTRP. These models were then applied to the expression levels of TCGA samples, generating predicted scores for drug sensitivity for each TCGA patient. Next, we evaluated the accessibility of each regulatory element in the corresponding TCGA patients using TCGA ATAC-seq signals, and further determined the associations between regulatory element accessibility and imputed drug response using Spearman correlation. Associations with |<italic toggle="yes">R</italic>| &gt;0.3 and FDR &lt;0.05 were considered as significant associations in each cancer type.</p>
    </sec>
    <sec id="SEC2-6">
      <title>Identification of enriched TFs and biological functions</title>
      <p>Enrichment analysis of TF binding sites was conducted for dysregulated elements using the Homer findMotifs.pl function and LOLA program, setting one condition's dysregulated CRE/SCREs as the foreground and the other's as the background (<xref rid="B52" ref-type="bibr">52</xref>). To gain a deeper understanding of the context specificity and essentiality of each significant TF (FDR &lt; 0.01), we analyzed their corresponding expression levels in TCGA pan-cancer samples, gene dependency scores in cancer cell lines, and clinical prognosis. Furthermore, we introduced the KnockTF datasets and presented the potential downstream targets.</p>
      <p>For biological functions, we employed the solo mode of Cistrome-GO program to perform pathway enrichment analysis by using the collections of gene sets from KEGG and GO-BP (<xref rid="B53" ref-type="bibr">53</xref>). A minimum-hypergeometric test was conducted to identify the enriched pathways with an FDR &lt; 0.2. The detailed information about association analyses were listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>.</p>
    </sec>
    <sec id="SEC2-7">
      <title>Identification of tumor-specific and cell type-specific CREs and SCREs</title>
      <p>To identify more CREs and SCREs that regulate oncogenes in tumor-specific and cell type-specific manners, we first selected the CREs and SCREs that demonstrated gained active modification or lost repressive modification in tumor samples compared with nonmalignant samples. We then employed a prioritization approach to select the most promising candidates from all association analyses based on the specific criteria. These criteria included: (i) enhanced expression of the associated gene, (ii) ranking within the top 5 for chromatin accessibility, (iii) ranking within the top 5 for eRNA activity and (iv) exhibiting an overlap of at least 50% in length with fewer than two <italic toggle="yes">cis-</italic>regulatory elements found in other cancer types. CREs and SCREs that met all these criteria were considered to have a high confidence level of tumor specificity and cancer-type specificity. Additionally, CREs and SCREs that satisfied three criteria achieved a median confidence level. Furthermore, CREs and SCREs that met two criteria were regarded as having a low confidence level.</p>
    </sec>
    <sec id="SEC2-8">
      <title>Web interface implementation</title>
      <p>All the metadata and analysis results were stored and managed using MySQL tables. The web interfaces were implemented using Hyper Text Markup Language (HTML), Cascading Style Sheets (CSS), and JavaScript (JS). To visualize all the analysis results, various statistical diagrams were shown by EChars and UCSC Genome Browser were implemented.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Data summary</title>
      <p>In the current release, TSCRE contains 138 carefully curated histone ChIP-seq datasets covering 1366 patient samples across 9 different histone marks and 17 different cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). Of these, 1034 samples were collected from patient tissues, while 332 samples were derived from cancer cell lines (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1C</xref>). Across 17 cancer types, a total of 18 64 941 dysregulated CREs and 68 253 dysregulated SCREs were identified in one of the following conditions: ‘tumor versus nonmalignant’, ‘metastasis versus primary’, ‘mutant versus wildtype’ and ‘subtype1 versus subtype2’ (Table <xref rid="tbl1" ref-type="table">1</xref>). Notably, approximately 95% of CREs and 99% of SCREs have been validated in at least one public resource, demonstrating the reproducibility and robustness of our data analyses.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>Statistics of dysregulated CREs and SCREs in TSCRE</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th colspan="2" align="center" rowspan="1">Tumor versus nonmalignant</th>
              <th colspan="2" align="center" rowspan="1">Metastasis versus primary</th>
              <th colspan="2" align="center" rowspan="1">Mutant versus wildtype</th>
              <th colspan="2" align="center" rowspan="1">Subtype1 versus Subtype2</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1">
                <inline-graphic xlink:href="zcad063figu1.jpg"/>
              </th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
              <th rowspan="1" colspan="1">CRE</th>
              <th rowspan="1" colspan="1">SCRE</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Colorectal cancer</td>
              <td rowspan="1" colspan="1">143 662</td>
              <td rowspan="1" colspan="1">4878</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Uterine leiomyoma</td>
              <td rowspan="1" colspan="1">68 805</td>
              <td rowspan="1" colspan="1">2481</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Gastric cancer</td>
              <td rowspan="1" colspan="1">58 686</td>
              <td rowspan="1" colspan="1">2339</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Prostate cancer</td>
              <td rowspan="1" colspan="1">40 833</td>
              <td rowspan="1" colspan="1">2422</td>
              <td rowspan="1" colspan="1">68805</td>
              <td rowspan="1" colspan="1">2170</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Liver cancer</td>
              <td rowspan="1" colspan="1">32 847</td>
              <td rowspan="1" colspan="1">1187</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kidney cancer</td>
              <td rowspan="1" colspan="1">32 209</td>
              <td rowspan="1" colspan="1">3000</td>
              <td rowspan="1" colspan="1">8</td>
              <td rowspan="1" colspan="1">98</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">341 735</td>
              <td rowspan="1" colspan="1">8502</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Glioma</td>
              <td rowspan="1" colspan="1">18 657</td>
              <td rowspan="1" colspan="1">1481</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Esophageal cancer</td>
              <td rowspan="1" colspan="1">7841</td>
              <td rowspan="1" colspan="1">442</td>
              <td rowspan="1" colspan="1">2145</td>
              <td rowspan="1" colspan="1">172</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">20 562</td>
              <td rowspan="1" colspan="1">560</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Follicular lymphoma</td>
              <td rowspan="1" colspan="1">257</td>
              <td rowspan="1" colspan="1">170</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Diffuse large B cell lymphoma</td>
              <td rowspan="1" colspan="1">339</td>
              <td rowspan="1" colspan="1">82</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Natural killer T-cell lymphoma</td>
              <td rowspan="1" colspan="1">27 784</td>
              <td rowspan="1" colspan="1">713</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lung cancer</td>
              <td rowspan="1" colspan="1">25 066</td>
              <td rowspan="1" colspan="1">1584</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Breast cancer</td>
              <td rowspan="1" colspan="1">543 577</td>
              <td rowspan="1" colspan="1">17 615</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">296 088</td>
              <td rowspan="1" colspan="1">11 537</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Head and neck cancer</td>
              <td rowspan="1" colspan="1">51 649</td>
              <td rowspan="1" colspan="1">3276</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">9796</td>
              <td rowspan="1" colspan="1">1052</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pancreatic cancer</td>
              <td rowspan="1" colspan="1">7198</td>
              <td rowspan="1" colspan="1">81</td>
              <td rowspan="1" colspan="1">59 098</td>
              <td rowspan="1" colspan="1">1669</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Osteosarcoma</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">193</td>
              <td rowspan="1" colspan="1">207</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Chronic lymphocytic leukemia</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">7101</td>
              <td rowspan="1" colspan="1">535</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">−</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Total</td>
              <td rowspan="1" colspan="1">1 059 410</td>
              <td rowspan="1" colspan="1">41 751</td>
              <td rowspan="1" colspan="1">130 249</td>
              <td rowspan="1" colspan="1">4316</td>
              <td rowspan="1" colspan="1">7101</td>
              <td rowspan="1" colspan="1">535</td>
              <td rowspan="1" colspan="1">668 181</td>
              <td rowspan="1" colspan="1">21651</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To facilitate further functional and mechanistic studies, systematic association analyses are integrated into TSCRE. First, we provide detailed gene annotation, associated TFBSs and somatic mutations for each dysregulated element. In addition to the nearest or overlapping genes, a total of 220 681 distal CREs and 44 639 distal SCREs were associated with specific genes through distal element-to-promoter loops. Additionally, 80.09% (1 493 595/1 864 941) of CREs and 99.96% (68 224/68 253) of SCREs exhibited one or more TFBSs. Moreover, 31 705 dysregulated CREs and 27 029 dysregulated SCREs had associated somatic mutations in the corresponding cancer type. These findings highlight the importance of <italic toggle="yes">cis-</italic>regulatory elements in addressing key issues related to cancer biology. Second, we accessed the cancer-type specificity of each regulatory element. Notably, a large proportion of CREs (83.8%) and SCREs (59.58%) show overlap with other regulatory elements in three or fewer cancer types, indicating a high degree of cancer-type specificity (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>). Third, we assessed the association between regulatory elements and imputed drug response in patients across various cancer types, providing a more direct and powerful evaluation of the role of CREs and SCREs in targeted therapy compared to <italic toggle="yes">in vitro</italic> cell lines. We obtained 20 812 864 associations between CRE accessibility and the imputed drug response, consisting of 6 531 763 associations detected from CTRP and 14 281 101 associations from GDSC. Similarly, 672 248 associations were found in SCREs. These data provide valuable insights into the potential impact of regulatory elements on drug response in cancer patients. The dysregulation of CRE and SCREs can influence transcriptional programs by facilitating or restricting the accessibility of transcript factor binding sites in a tumor-specific and cell type-specific manner, thereby mediating the activation of cancer-associated pathways. We further identified all enriched TFs and pathways for each study to promote follow-up functional and mechanistic studies. Additionally, we collected a comprehensive dataset comprising 683 TF knockout microarrays and RNA-seq data from the KnockTF database, enabling the identification of potential downstream targets.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Data access</title>
      <p>TSCRE provides a user-friendly web interface, allowing users to intuitively explore and search any CRE or SCRE:</p>
      <p><bold>Explore</bold>. Users can select the cancer type(s), histone marker(s) and condition(s) of interest either through an interactive heatmap or a summary list. For example, if users are interested in studying tumor-specific regulatory elements in colorectal cancer, they can easily choose ‘colorectal cancer’ and ‘Tumor vs Nonmalignant’ from the metadata selection facet (Figure <xref rid="F2" ref-type="fig">2A</xref>). Subsequently, the relevant heatmap cells are retrieved (Figure <xref rid="F2" ref-type="fig">2A</xref>), and upon clicking on a specific cell, a dataset list is presented (Figure <xref rid="F2" ref-type="fig">2B</xref>). Data in TSCRE is organized into two layers: CRE and SCRE. By clicking on ‘CRE’ or ‘SCRE’ in a dataset of interest, users will be directed to a detailed page that provides study and sample details, CRE/SCRE information, as well as TF and pathway enrichment analysis. The CRE/SCRE information section shows all dysregulated elements and summarizes the number of association analyses conducted for each element (Figure <xref rid="F2" ref-type="fig">2C</xref>). Clicking on individual CRE ID shows the detailed information for each dysregulated element. The TF enrichment analysis section displays significantly enriched TFs identified in this study (Figure <xref rid="F2" ref-type="fig">2D</xref>). Some visualized figures are generated in real time to allow investigation of the cancer-type specificity and potential targets of enriched TFs (Figure <xref rid="F2" ref-type="fig">2E</xref>). For instance, HNF4A, a well-established gastrointestinal-specific transcription factor (<xref rid="B54" ref-type="bibr">54</xref>), ranked as the second most enriched TF in colorectal cancer-specific CREs (Figure <xref rid="F2" ref-type="fig">2D</xref>). HNF4A exhibited the highest expression levels in both colorectal cancer tissues and cell lines, regulated many target genes and was essential for the viability of the majority of colorectal cancer cells in the unbiased high-throughput CRISPR screening (Figure <xref rid="F2" ref-type="fig">2E</xref>). The pathway enrichment analysis section displays all enriched pathways associated with dysregulated elements and the top 10 pathways are shown in a bubble plot.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>A schematic workflow of the browse interface in TSCRE. <bold>(A)</bold> TSCRE provides an interactive heatmap and a summary list to browse and select studies of interest. Snapshot of results for colorectal cancer in ‘Tumor vs Nonmalignant’ condition. <bold>(B)</bold> A summary list is shown when clicking on a specific heatmap cell. Data in TSCRE is organized into two layers: CRE and SCRE. <bold>(C)</bold> The CRE information section shows all dysregulated elements and summarizes the number of association analyses conducted for each element. <bold>(D)</bold> Snapshot of HNF4A as the second most enriched TF. <bold>(E)</bold> Click the ‘eye’ button to get the expression levels of HNF4A in pan-cancer tissues and cell lines, the gene dependency scores, as well as potential target genes.</p>
        </caption>
        <graphic xlink:href="zcad063fig2" position="float"/>
      </fig>
      <p><bold>Search</bold>. TSCRE provides three modes to query the database, according to your interest in specific genes, transcription factors, and genomic regions. All the search results are summarized with real-time statistical diagrams and further filtered by check boxes.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Tumor-specific CREs and SCREs identified in TSCRE</title>
      <p>TSCRE is a valuable resource to explore and discover cancer biomarkers. Through the analysis of the ‘Tumor vs Nonmalignant’ comparison, we identified 918 CREs and 405 SCREs that exhibited a high confidence level of tumor specificity and cancer-type specificity (see Materials and methods). Additionally, 24 821 CREs and 1948 SCREs met the criteria for the median confidence level. Furthermore, we identified 151 273 CREs and 3880 SCREs with a low confidence level (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). These <italic toggle="yes">cis-</italic>regulatory elements may aid in the discovery of candidate cancer biomarkers and enhance our knowledge of regulatory mechanisms in cancer. For example, <italic toggle="yes">CD70</italic> is reported as a tumor-specific biomarker in kidney cancer, which promotes immune escape by inducing cytotoxic effects on B and T lymphocytes. Using TSCRE, we found <italic toggle="yes">CD70</italic> was regulated by a distal enhancer (‘Pair_41_CRE330’) in kidney cancer, which were further validated by FANTOME5 enhancers and pan-cancer ATAC-seq links (Figure <xref rid="F3" ref-type="fig">3A</xref>). Notably, this enhancer exhibits a significant increase in H3K27ac signal in kidney cancer compared to nonmalignant samples (Figure <xref rid="F3" ref-type="fig">3B</xref>), which coincides with the upregulation of <italic toggle="yes">CD70</italic> (Figure <xref rid="F3" ref-type="fig">3C</xref>). Moreover, this enhancer demonstrated a high degree of cell type specificity, as it ranked first in chromatin accessibility (Figure <xref rid="F3" ref-type="fig">3D</xref>) and second in eRNA activity (Figure <xref rid="F3" ref-type="fig">3E</xref>) within kidney cancer. Especially, only a single CRE in colon cancer exhibits partial overlap with this enhancer (Figure <xref rid="F3" ref-type="fig">3A</xref>). These findings indicate this enhancer associated with <italic toggle="yes">CD70</italic> regulation is highly specific to kidney cancer. Another notable case is <italic toggle="yes">MERTK</italic> gene, which is known as an oncogene that promotes breast cancer progression (<xref rid="B12" ref-type="bibr">12</xref>). Consistently, nonmalignant samples encompass repressive CREs (known as silencers in SilencerDB) associated with <italic toggle="yes">MERTK</italic>. However, across all subtypes of breast cancer, there is a significant loss of H3K27me3 modification, coinciding with the upregulation of MERTK in most subtypes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3</xref>). These results suggest that dysregulated CREs in TSCRE are highly specific to tumorigenesis and underscore their potential role in elucidating the molecular mechanisms underlying pathogenesis.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>The detailed information of a distal CRE for <italic toggle="yes">CD70</italic>. <bold>(A)</bold> Visualization of ‘Pair_41_CRE330’ using UCSC Genome Browser. (B, C) A significant increase in H3K27ac signal <bold>(B)</bold> and mRNA expression <bold>(C)</bold> was observed in kidney cancer. (D, E) Kidney cancer exhibits the highest chromatin accessibility <bold>(D)</bold> and the second-highest level of eRNA activity <bold>(E)</bold> within this CRE.</p>
        </caption>
        <graphic xlink:href="zcad063fig3" position="float"/>
      </fig>
      <p>Similarly, dysregulated SCREs are also highly specific to tumorigenesis (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3B</xref>). For example, <italic toggle="yes">PDX1</italic>, a potential tumor marker in colorectal cancer (<xref rid="B55" ref-type="bibr">55</xref>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S4A</xref>), contains both a lost repressive SCRE (‘Pair_18_SCRE66’) and a gained active SCRE (‘Pair_10_SCRE127’, a super-enhancer cataloged in Reference (<xref rid="B34" ref-type="bibr">34</xref>)) in colorectal cancer. In nonmalignant tissues, <italic toggle="yes">PDX1</italic> is characterized by the presence of H3K27me3 signal and the absence of H3K27ac. In contrast, it undergoes a reduction in H3K27me3 and an increase in H3K27ac during tumorigenesis, accompanied by elevated mRNA expression. Additionally, this SCRE shows high cell type specificity, ranking first in both accessibility and eRNA activity.</p>
      <p>In addition, TSCRE serves as a valuable platform for identifying potential therapeutic targets associated with dysregulated elements. An exemplary case is the EGFR gene, which exhibits frequent overexpression in basal breast cancer and contributes to the aggressive behavior of this subtype (<xref rid="B56" ref-type="bibr">56</xref>). Recent investigations have explored EGFR inhibitors, such as gefitinib and erlotinib, as potential treatment modalities for basal breast cancer (<xref rid="B56" ref-type="bibr">56</xref>). Encouragingly, our findings demonstrate a significant association between the drug response to gefitinib and erlotinib and a gained active SCRE ("Pair_92_SCRE61’, a super-enhancer cataloged in Reference (<xref rid="B34" ref-type="bibr">34</xref>)) in EGFR specific to basal breast cancer (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S5</xref>). Remarkably, within TSCRE, a substantial proportion of CREs (628 993 out of 1 864 941) and SCREs (25 964 out of 68 253) are linked to drugs, suggesting their potential involvement in drug response or as therapeutic targets.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>TSCRE is a comprehensive open resource for providing dysregulated CREs and SCREs through the re-analysis of publicly available ChIP-seq data. In comparison to other existing databases, TSCRE possesses the following advantages: (i) To the best of our knowledge, TSCRE is the first comprehensive database focusing specifically on <italic toggle="yes">cis-</italic>regulatory elements in a highly cancer-associated context; (ii) TSCRE is the only database emphasizing the roles of both CREs and SCREs. (iii) In addition to super-enhancers, TSCRE also provides super repressive elements and other broad regions, which were modified with repressive marks (e.g. H3K27m3, H3K9me3) or other active marks (e.g. H3K4me3, H3K36me3). (iv) TSCRE provides detailed annotations for each CRE and SCRE, including gene annotation, mRNA expression, clinical prognosis, associated TFBSs, associated mutations and cancer-type specificity. These annotations assist biologists in identifying relevant biological features and discover novel cancer biomarkers. (v) TSCRE assesses the associations between dysregulated elements and drug response in cancer patients, potentially enabling more direct and impactful target therapy. (vi) TSCRE integrates the results of pathway and TF enrichment analysis to facilitate follow-up functional and mechanistic studies.</p>
    <p>In the future, TSCRE will be continuously updated as new histone modification profiling data become available in public databases. We also plan to incorporate other epigenetic marks, such as DNA methylation, and more drug response dataset into TSCRE. Additionally, we strongly encourage users to contribute to TSCRE by uploading their own data.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>zcad063_Supplemental_Files</label>
      <media xlink:href="zcad063_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>YYZ was supported by the National Natural Science Foundation of China (32200538), Shenzhen Science and Technology Innovation Commission (JCYJ20220530144815036, JCYJ20230807110309019), the Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University (ZSQYBRJH0025). XPS was supported by the National Natural Science Foundation of China (82170177/H0809), the Natural Science Foundation of Guangdong Province (2021A1515011334 and 2023A1515011976). XTL was supported by the National Natural Science Foundation of China (32200542).</p>
    <p><italic toggle="yes">Author contributions</italic>: <bold>Y.Y. Zheng:</bold> conceptualization, resources, supervision, funding acquisition, methodology, writing–original draft, writing–review and editing. <bold>J. Ren:</bold> resources, supervision, methodology, writing–review and editing. <bold>X.P. Shi:</bold> resources, supervision, funding acquisition, methodology, writing–review and editing. <bold>G.J. Peng:</bold> data curation, data analysis, writing–original draft, writing–review and editing. <bold>B.Y. Liu:</bold> data curation, data analysis, writing–original draft, writing–review and editing. <bold>M.H. Zheng:</bold> website construction, visualization, methodology, writing–review and editing. <bold>L.W.Y. Zhang:</bold> website construction, visualization, methodology, writing–review and editing. <bold>H.Q. Li:</bold> website construction, methodology. <bold>MN. Liu:</bold> data curation, writing–review and editing. <bold>Y. Liang:</bold> data curation, writing–review and editing. <bold>T.J. Chen:</bold> website construction, methodology. <bold>X.T. Luo:</bold> resources, methodology and funding acquisition.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>No new data were generated or analysed in support of this research.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcad063#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Cancer Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>The Young Scientists Fund of the National Natural Science Foundation of China [32200538, 32200542]; Shenzhen Science and Technology Innovation Commission [JCYJ20220530144815036, JCYJ20230807110309019]; The Natural Science Foundation of Guangdong Province [2021A1515011334, 2023A1515011976]; The National Natural Science Foundation of China [82170177/H0809]; Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University [ZSQYBRJH0025].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ong</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Corces</surname><given-names>V.G.</given-names></string-name></person-group><article-title>Enhancer function: new insights into the regulation of tissue-specific gene expression</article-title>. <source>Nat. Rev. Genet.</source><year>2011</year>; <volume>12</volume>:<fpage>283</fpage>–<lpage>293</lpage>.<pub-id pub-id-type="pmid">21358745</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pang</surname><given-names>B.</given-names></string-name>, <string-name><surname>van Weerd</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Hamoen</surname><given-names>F.L.</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>M.P.</given-names></string-name></person-group><article-title>Identification of non-coding silencer elements and their regulation of gene expression</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><year>2023</year>; <volume>24</volume>:<fpage>383</fpage>–<lpage>395</lpage>.<pub-id pub-id-type="pmid">36344659</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andersson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Sandelin</surname><given-names>A.</given-names></string-name></person-group><article-title>Determinants of enhancer and promoter activities of regulatory elements</article-title>. <source>Nat. Rev. Genet.</source><year>2020</year>; <volume>21</volume>:<fpage>71</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">31605096</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Madani Tonekaboni</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Haibe-Kains</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lupien</surname><given-names>M.</given-names></string-name></person-group><article-title>Large organized chromatin lysine domains help distinguish primitive from differentiated cell populations</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>499</fpage>.<pub-id pub-id-type="pmid">33479238</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whyte</surname><given-names>W.A.</given-names></string-name>, <string-name><surname>Orlando</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Hnisz</surname><given-names>D.</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Kagey</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Rahl</surname><given-names>P.B.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Master transcription factors and mediator establish super-enhancers at key cell identity genes</article-title>. <source>Cell</source>. <year>2013</year>; <volume>153</volume>:<fpage>307</fpage>–<lpage>319</lpage>.<pub-id pub-id-type="pmid">23582322</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Loh</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Tng</surname><given-names>J.Q.</given-names></string-name>, <string-name><surname>Lim</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Raju</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lieberman Aiden</surname><given-names>E.</given-names></string-name>, <string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Manikandan</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>H3K27me3-rich genomic regions can function as silencers to repress gene expression via chromatin interactions</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>719</fpage>.<pub-id pub-id-type="pmid">33514712</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hsieh</surname><given-names>I.Y.</given-names></string-name>, <string-name><surname>He</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>B.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>B.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>G.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis</article-title>. <source>Biomed. Pharmacother.</source><year>2020</year>; <volume>123</volume>:<fpage>109728</fpage>.<pub-id pub-id-type="pmid">31846842</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Loven</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hoke</surname><given-names>H.A.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Lau</surname><given-names>A.</given-names></string-name>, <string-name><surname>Orlando</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Vakoc</surname><given-names>C.R.</given-names></string-name>, <string-name><surname>Bradner</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title>. <source>Cell</source>. <year>2013</year>; <volume>153</volume>:<fpage>320</fpage>–<lpage>334</lpage>.<pub-id pub-id-type="pmid">23582323</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>X.</given-names></string-name>, <string-name><surname>Su</surname><given-names>J.</given-names></string-name>, <string-name><surname>Rodriguez</surname><given-names>B.</given-names></string-name>, <string-name><surname>Xi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes</article-title>. <source>Nat. Genet.</source><year>2015</year>; <volume>47</volume>:<fpage>1149</fpage>–<lpage>1157</lpage>.<pub-id pub-id-type="pmid">26301496</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Saiakhova</surname><given-names>A.</given-names></string-name>, <string-name><surname>Corradin</surname><given-names>O.</given-names></string-name>, <string-name><surname>Luppino</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Lovrenert</surname><given-names>K.</given-names></string-name>, <string-name><surname>Bartels</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Morrow</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Mack</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Dhillon</surname><given-names>G.</given-names></string-name>, <string-name><surname>Beard</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome</article-title>. <source>Nat. Commun.</source><year>2017</year>; <volume>8</volume>:<fpage>14400</fpage>.<pub-id pub-id-type="pmid">28169291</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Maryam</surname><given-names>A.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ramakrishnan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>V.W.S.</given-names></string-name>, <string-name><surname>Cheuk</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>2242</fpage>.<pub-id pub-id-type="pmid">33854062</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Meng</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Yi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Broad genic repression domains signify enhanced silencing of oncogenes</article-title>. <source>Nat. Commun.</source><year>2020</year>; <volume>11</volume>:<fpage>5560</fpage>.<pub-id pub-id-type="pmid">33144558</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bouras</surname><given-names>E.</given-names></string-name>, <string-name><surname>Karakioulaki</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bougioukas</surname><given-names>K.I.</given-names></string-name>, <string-name><surname>Aivaliotis</surname><given-names>M.</given-names></string-name>, <string-name><surname>Tzimagiorgis</surname><given-names>G.</given-names></string-name>, <string-name><surname>Chourdakis</surname><given-names>M.</given-names></string-name></person-group><article-title>Gene promoter methylation and cancer: an umbrella review</article-title>. <source>Gene</source>. <year>2019</year>; <volume>710</volume>:<fpage>333</fpage>–<lpage>340</lpage>.<pub-id pub-id-type="pmid">31202904</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qamra</surname><given-names>A.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>M.</given-names></string-name>, <string-name><surname>Padmanabhan</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>J.J.T.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Leong</surname><given-names>Y.S.</given-names></string-name>, <string-name><surname>Lee Lim</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Ooi</surname><given-names>W.F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma</article-title>. <source>Cancer Discov.</source><year>2017</year>; <volume>7</volume>:<fpage>630</fpage>–<lpage>651</lpage>.<pub-id pub-id-type="pmid">28320776</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mack</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Pajtler</surname><given-names>K.W.</given-names></string-name>, <string-name><surname>Chavez</surname><given-names>L.</given-names></string-name>, <string-name><surname>Okonechnikov</surname><given-names>K.</given-names></string-name>, <string-name><surname>Bertrand</surname><given-names>K.C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Erkek</surname><given-names>S.</given-names></string-name>, <string-name><surname>Federation</surname><given-names>A.</given-names></string-name>, <string-name><surname>Song</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling</article-title>. <source>Nature</source>. <year>2018</year>; <volume>553</volume>:<fpage>101</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">29258295</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>G.H.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Qi</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Teng</surname><given-names>X.Q.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H.H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>J.</given-names></string-name></person-group><article-title>Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance</article-title>. <source>J. Exp. Clin. Cancer Res.</source><year>2021</year>; <volume>40</volume>:<fpage>174</fpage>.<pub-id pub-id-type="pmid">34011395</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name></person-group><article-title>Super-enhancer function and its application in cancer targeted therapy</article-title>. <source>NPJ Precis. Oncol.</source><year>2020</year>; <volume>4</volume>:<fpage>2</fpage>.<pub-id pub-id-type="pmid">32128448</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hou</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>W.</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>F.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name></person-group><article-title>Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma</article-title>. <source>J. Transl. Med.</source><year>2011</year>; <volume>9</volume>:<fpage>39</fpage>.<pub-id pub-id-type="pmid">21481255</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tseng</surname><given-names>A.W.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Breslin</surname><given-names>M.B.</given-names></string-name>, <string-name><surname>Lan</surname><given-names>M.S.</given-names></string-name></person-group><article-title>Tumor-specific promoter-driven adenoviral therapy for insulinoma</article-title>. <source>Cell Oncol (Dordr)</source>. <year>2016</year>; <volume>39</volume>:<fpage>279</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">26902080</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muratani</surname><given-names>M.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>N.</given-names></string-name>, <string-name><surname>Ooi</surname><given-names>W.F.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Qamra</surname><given-names>A.</given-names></string-name>, <string-name><surname>Tay</surname><given-names>S.T.</given-names></string-name>, <string-name><surname>Malik</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements</article-title>. <source>Nat. Commun.</source><year>2014</year>; <volume>5</volume>:<fpage>4361</fpage>.<pub-id pub-id-type="pmid">25008978</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heintzman</surname><given-names>N.D.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Hon</surname><given-names>G.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ching</surname><given-names>C.W.</given-names></string-name>, <string-name><surname>Hawkins</surname><given-names>R.D.</given-names></string-name>, <string-name><surname>Barrera</surname><given-names>L.O.</given-names></string-name>, <string-name><surname>Van Calcar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ching</surname><given-names>K.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome</article-title>. <source>Nat. Genet.</source><year>2007</year>; <volume>39</volume>:<fpage>311</fpage>–<lpage>318</lpage>.<pub-id pub-id-type="pmid">17277777</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akhtar-Zaidi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Cowper-Sal-lari</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corradin</surname><given-names>O.</given-names></string-name>, <string-name><surname>Saiakhova</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bartels</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Balasubramanian</surname><given-names>D.</given-names></string-name>, <string-name><surname>Myeroff</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lutterbaugh</surname><given-names>J.</given-names></string-name>, <string-name><surname>Jarrar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kalady</surname><given-names>M.F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Epigenomic enhancer profiling defines a signature of colon cancer</article-title>. <source>Science</source>. <year>2012</year>; <volume>336</volume>:<fpage>736</fpage>–<lpage>739</lpage>.<pub-id pub-id-type="pmid">22499810</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hitz</surname><given-names>B.C.</given-names></string-name>, <string-name><surname>Gabdank</surname><given-names>I.</given-names></string-name>, <string-name><surname>Hilton</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Kagda</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>B.</given-names></string-name>, <string-name><surname>Myers</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Sud</surname><given-names>P.</given-names></string-name>, <string-name><surname>Jou</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>New developments on the Encyclopedia of DNA Elements (ENCODE) data portal</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D882</fpage>–<lpage>D889</lpage>.<pub-id pub-id-type="pmid">31713622</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mei</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D729</fpage>–<lpage>D735</lpage>.<pub-id pub-id-type="pmid">30462313</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zou</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Ohta</surname><given-names>T.</given-names></string-name>, <string-name><surname>Miura</surname><given-names>F.</given-names></string-name>, <string-name><surname>Oki</surname><given-names>S.</given-names></string-name></person-group><article-title>ChIP-Atlas 2021 update: a data-mining suite for exploring epigenomic landscapes by fully integrating ChIP-seq, ATAC-seq and bisulfite-seq data</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>W175</fpage>–<lpage>W182</lpage>.<pub-id pub-id-type="pmid">35325188</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Song</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>SEdb 2.0: a comprehensive super-enhancer database of human and mouse</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D280</fpage>–<lpage>D290</lpage>.<pub-id pub-id-type="pmid">36318264</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xing</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name></person-group><article-title>SEA version 3.0: a comprehensive extension and update of the Super-Enhancer archive</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D198</fpage>–<lpage>D203</lpage>.<pub-id pub-id-type="pmid">31667506</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name></person-group><article-title>dbSUPER: a database of super-enhancers in mouse and human genome</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D164</fpage>–<lpage>D171</lpage>.<pub-id pub-id-type="pmid">26438538</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corces</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Granja</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Shams</surname><given-names>S.</given-names></string-name>, <string-name><surname>Louie</surname><given-names>B.H.</given-names></string-name>, <string-name><surname>Seoane</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>W.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Groeneveld</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>C.K.</given-names></string-name>, <string-name><surname>Cho</surname><given-names>S.W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The chromatin accessibility landscape of primary human cancers</article-title>. <source>Science</source>. <year>2018</year>; <volume>362</volume>:<fpage>eaav1898</fpage>.<pub-id pub-id-type="pmid">30361341</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Song</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kuang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>D.</given-names></string-name>, <string-name><surname>Choudhary</surname><given-names>M.N.K.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The 3D genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions</article-title>. <source>Genome Biol.</source><year>2018</year>; <volume>19</volume>:<fpage>151</fpage>.<pub-id pub-id-type="pmid">30286773</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noguchi</surname><given-names>S.</given-names></string-name>, <string-name><surname>Arakawa</surname><given-names>T.</given-names></string-name>, <string-name><surname>Fukuda</surname><given-names>S.</given-names></string-name>, <string-name><surname>Furuno</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hasegawa</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hori</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ishikawa-Kato</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kaida</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kaiho</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kanamori-Katayama</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>FANTOM5 CAGE profiles of human and mouse samples</article-title>. <source>Sci. Data</source>. <year>2017</year>; <volume>4</volume>:<fpage>170112</fpage>.<pub-id pub-id-type="pmid">28850106</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fishilevich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Nudel</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rappaport</surname><given-names>N.</given-names></string-name>, <string-name><surname>Hadar</surname><given-names>R.</given-names></string-name>, <string-name><surname>Plaschkes</surname><given-names>I.</given-names></string-name>, <string-name><surname>Iny Stein</surname><given-names>T.</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kohn</surname><given-names>A.</given-names></string-name>, <string-name><surname>Twik</surname><given-names>M.</given-names></string-name>, <string-name><surname>Safran</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>GeneHancer: genome-wide integration of enhancers and target genes in GeneCards</article-title>. <source>Database (Oxford)</source>. <year>2017</year>; <volume>2017</volume>:<fpage>bax028</fpage>.<pub-id pub-id-type="pmid">28605766</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeng</surname><given-names>W.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>X.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>R.</given-names></string-name></person-group><article-title>SilencerDB: a comprehensive database of silencers</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D221</fpage>–<lpage>D228</lpage>.<pub-id pub-id-type="pmid">33045745</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hnisz</surname><given-names>D.</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Lau</surname><given-names>A.</given-names></string-name>, <string-name><surname>Saint-Andre</surname><given-names>V.</given-names></string-name>, <string-name><surname>Sigova</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Hoke</surname><given-names>H.A.</given-names></string-name>, <string-name><surname>Young</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Super-enhancers in the control of cell identity and disease</article-title>. <source>Cell</source>. <year>2013</year>; <volume>155</volume>:<fpage>934</fpage>–<lpage>947</lpage>.<pub-id pub-id-type="pmid">24119843</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>F.W.</given-names></string-name>, <string-name><surname>Jane-Valbuena</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kryukov</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>E.R.</given-names></string-name>, <string-name><surname>Barretina</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gelfand</surname><given-names>E.T.</given-names></string-name>, <string-name><surname>Bielski</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Next-generation characterization of the Cancer Cell Line Encyclopedia</article-title>. <source>Nature</source>. <year>2019</year>; <volume>569</volume>:<fpage>503</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research, N.</collab><string-name><surname>Weinstein</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Collisson</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Mills</surname><given-names>G.B.</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>K.R.</given-names></string-name>, <string-name><surname>Ozenberger</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Ellrott</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shmulevich</surname><given-names>I.</given-names></string-name>, <string-name><surname>Sander</surname><given-names>C.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>J.M</given-names></string-name></person-group><article-title>The cancer genome atlas pan-cancer analysis project</article-title>. <source>Nat. Genet.</source><year>2013</year>; <volume>45</volume>:<fpage>1113</fpage>–<lpage>1120</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>H.</given-names></string-name></person-group><article-title>A high-resolution map of Human enhancer RNA loci characterizes super-enhancer activities in cancer</article-title>. <source>Cancer Cell</source>. <year>2020</year>; <volume>38</volume>:<fpage>701</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">33007258</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tate</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Bamford</surname><given-names>S.</given-names></string-name>, <string-name><surname>Jubb</surname><given-names>H.C.</given-names></string-name>, <string-name><surname>Sondka</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Beare</surname><given-names>D.M.</given-names></string-name>, <string-name><surname>Bindal</surname><given-names>N.</given-names></string-name>, <string-name><surname>Boutselakis</surname><given-names>H.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Creatore</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dawson</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>COSMIC: the catalogue of somatic mutations In cancer</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D941</fpage>–<lpage>D947</lpage>.<pub-id pub-id-type="pmid">30371878</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Song</surname><given-names>C.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ning</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>KnockTF: a comprehensive human gene expression profile database with knockdown/knockout of transcription factors</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D93</fpage>–<lpage>D100</lpage>.<pub-id pub-id-type="pmid">31598675</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rees</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Seashore-Ludlow</surname><given-names>B.</given-names></string-name>, <string-name><surname>Cheah</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Price</surname><given-names>E.V.</given-names></string-name>, <string-name><surname>Gill</surname><given-names>S.</given-names></string-name>, <string-name><surname>Javaid</surname><given-names>S.</given-names></string-name>, <string-name><surname>Coletti</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>V.L.</given-names></string-name>, <string-name><surname>Bodycombe</surname><given-names>N.E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</article-title>. <source>Nat. Chem. Biol.</source><year>2016</year>; <volume>12</volume>:<fpage>109</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">26656090</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Soares</surname><given-names>J.</given-names></string-name>, <string-name><surname>Greninger</surname><given-names>P.</given-names></string-name>, <string-name><surname>Edelman</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Lightfoot</surname><given-names>H.</given-names></string-name>, <string-name><surname>Forbes</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bindal</surname><given-names>N.</given-names></string-name>, <string-name><surname>Beare</surname><given-names>D.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>I.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D955</fpage>–<lpage>D961</lpage>.<pub-id pub-id-type="pmid">23180760</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name></person-group><article-title>Fast and accurate long-read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>. <year>2010</year>; <volume>26</volume>:<fpage>589</fpage>–<lpage>595</lpage>.<pub-id pub-id-type="pmid">20080505</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Handsaker</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wysoker</surname><given-names>A.</given-names></string-name>, <string-name><surname>Fennell</surname><given-names>T.</given-names></string-name>, <string-name><surname>Ruan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Homer</surname><given-names>N.</given-names></string-name>, <string-name><surname>Marth</surname><given-names>G.</given-names></string-name>, <string-name><surname>Abecasis</surname><given-names>G.</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name><collab>Genome Project Data Processing, S</collab></person-group><article-title>The sequence alignment/map format and SAMtools</article-title>. <source>Bioinformatics</source>. <year>2009</year>; <volume>25</volume>:<fpage>2078</fpage>–<lpage>2079</lpage>.<pub-id pub-id-type="pmid">19505943</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quinlan</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>I.M.</given-names></string-name></person-group><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title>. <source>Bioinformatics</source>. <year>2010</year>; <volume>26</volume>:<fpage>841</fpage>–<lpage>842</lpage>.<pub-id pub-id-type="pmid">20110278</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>T.</given-names></string-name></person-group><article-title>Use model-based analysis of ChIP-Seq (MACS) to analyze short reads generated by sequencing protein-DNA interactions in embryonic stem cells</article-title>. <source>Methods Mol. Biol.</source><year>2014</year>; <volume>1150</volume>:<fpage>81</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">24743991</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>D.</given-names></string-name>, <string-name><surname>Langmead</surname><given-names>B.</given-names></string-name>, <string-name><surname>Salzberg</surname><given-names>S.L.</given-names></string-name></person-group><article-title>HISAT: a fast spliced aligner with low memory requirements</article-title>. <source>Nat. Methods</source>. <year>2015</year>; <volume>12</volume>:<fpage>357</fpage>–<lpage>360</lpage>.<pub-id pub-id-type="pmid">25751142</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anders</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pyl</surname><given-names>P.T.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name></person-group><article-title>HTSeq–a Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source>. <year>2015</year>; <volume>31</volume>:<fpage>166</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">25260700</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name>, <string-name><surname>Anders</surname><given-names>S.</given-names></string-name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ross-Innes</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Stark</surname><given-names>R.</given-names></string-name>, <string-name><surname>Teschendorff</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Ali</surname><given-names>H.R.</given-names></string-name>, <string-name><surname>Dunning</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>G.D.</given-names></string-name>, <string-name><surname>Gojis</surname><given-names>O.</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>I.O.</given-names></string-name>, <string-name><surname>Green</surname><given-names>A.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Differential oestrogen receptor binding is associated with clinical outcome in breast cancer</article-title>. <source>Nature</source>. <year>2012</year>; <volume>481</volume>:<fpage>389</fpage>–<lpage>393</lpage>.<pub-id pub-id-type="pmid">22217937</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heinz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Benner</surname><given-names>C.</given-names></string-name>, <string-name><surname>Spann</surname><given-names>N.</given-names></string-name>, <string-name><surname>Bertolino</surname><given-names>E.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y.C.</given-names></string-name>, <string-name><surname>Laslo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>J.X.</given-names></string-name>, <string-name><surname>Murre</surname><given-names>C.</given-names></string-name>, <string-name><surname>Singh</surname><given-names>H.</given-names></string-name>, <string-name><surname>Glass</surname><given-names>C.K.</given-names></string-name></person-group><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title>. <source>Mol. Cell</source>. <year>2010</year>; <volume>38</volume>:<fpage>576</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">20513432</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maeser</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gruener</surname><given-names>R.F.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>R.S.</given-names></string-name></person-group><article-title>oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data</article-title>. <source>Brief Bioinform.</source><year>2021</year>; <volume>22</volume>:<fpage>bbab260</fpage>.<pub-id pub-id-type="pmid">34260682</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheffield</surname><given-names>N.C.</given-names></string-name>, <string-name><surname>Bock</surname><given-names>C.</given-names></string-name></person-group><article-title>LOLA: enrichment analysis for genomic region sets and regulatory elements in R and bioconductor</article-title>. <source>Bioinformatics</source>. <year>2016</year>; <volume>32</volume>:<fpage>587</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">26508757</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>X.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.S.</given-names></string-name></person-group><article-title>Cistrome-GO: a web server for functional enrichment analysis of transcription factor ChIP-seq peaks</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>W206</fpage>–<lpage>W211</lpage>.<pub-id pub-id-type="pmid">31053864</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>W.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>J.</given-names></string-name></person-group><article-title>The role of hepatocyte nuclear factor 4alpha (HNF4alpha) in tumorigenesis</article-title>. <source>Front. Oncol.</source><year>2022</year>; <volume>12</volume>:<fpage>1011230</fpage>.<pub-id pub-id-type="pmid">36249028</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ballian</surname><given-names>N.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Brunicardi</surname><given-names>F.C.</given-names></string-name></person-group><article-title>Transcription factor PDX-1 in human colorectal adenocarcinoma: a potential tumor marker?</article-title>. <source>World J. Gastroenterol.</source><year>2008</year>; <volume>14</volume>:<fpage>5823</fpage>–<lpage>5826</lpage>.<pub-id pub-id-type="pmid">18855980</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Masuda</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bartholomeusz</surname><given-names>C.</given-names></string-name>, <string-name><surname>Doihara</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hortobagyi</surname><given-names>G.N.</given-names></string-name>, <string-name><surname>Ueno</surname><given-names>N.T.</given-names></string-name></person-group><article-title>Role of epidermal growth factor receptor in breast cancer</article-title>. <source>Breast Cancer Res. Treat.</source><year>2012</year>; <volume>136</volume>:<fpage>331</fpage>–<lpage>345</lpage>.<pub-id pub-id-type="pmid">23073759</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
